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ABSTRACT 
During development, the nervous system is a sensitive target for chemical 
exposure in both humans and animal models, and early life-stage exposures can lead to 
long-term effects on motor activity, sensory function, and cognition. Currently, there are 
minimal to no developmental neurotoxicity (DNT) data available for thousands of 
chemicals used in commerce, and it is impractical to screen these chemicals in rodent 
models using the existing DNT test guideline, as this test is costly, time- and animal-
intensive, and low-throughput. Therefore, there is a recognized need to use alternative 
non-mammalian models to support screening and prioritization of chemicals for DNT 
testing, as well as hypothesis-driven studies that may help uncover mechanisms of DNT 
for pesticides and understudied high-production volume chemicals in commerce. Using 
zebrafish as an animal model, the objectives of this dissertation were to: 1) develop a 
high-content screening (HCS) assay for rapid and cost-effective identification of potential 
developmental neurotoxicants during zebrafish embryogenesis, and 2) begin investigating 
the mechanism of action of abamectin – an insecticide identified as a positive hit in our 
HCS assay – within zebrafish embryos. Data presented within Chapter 2 suggests that, 
compared to existing zebrafish-based assays, our HCS assay provides a simpler, 
streamlined discovery platform for identifying and prioritizing potential developmental 
neurotoxicants with: 1) increased sample sizes; (2) broad concentration−response format; 
(3) short assay duration (∼22 h total); and (4) minimal technical grade test material 
needed for screening. Data presented within Chapter 3 suggests that 1) abamectin induces 
vi 
rapid and reversible hypoactivity within early zebrafish embryos, 2) abamectin-induced 
hypoactivity is blocked by pretreatment with γ-aminobutyric acid (GABA) antagonists, 
and 3) zebrafish and mammalian ionotropic GABA receptor subunits are homologous – 
suggesting that these findings may have relevance to rodent models and humans. Overall, 
our findings suggest that zebrafish-based behavioral assays can be used within a tiered 
regulatory toxicity testing framework to help screen and prioritize chemicals for DNT 
testing in rodent models and develop hypothesis-driven studies in zebrafish embryos. 
Therefore, our HCS assay, in combination with follow-up studies, provides a rapid, cost-
effective method for identifying and characterizing potential developmental 
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1.1 TOXICITY TESTING: CHEMICALS IN GLOBAL COMMERCE 
 Globally, thousands of industrial chemicals, including basic chemicals (e.g., 
petrochemicals, basic inorganics, polymers), specialty chemicals (e.g., pesticides, paints, 
colorants), and consumer chemicals (e.g., detergents and soaps), are produced on a daily 
basis (European Chemical Industry Council, 2014). From 2002 to 2012 alone, total world 
chemical sales doubled from $2.338 trillion to $5.364 trillion (European Chemical 
Industry Council, 2014). In the United States (US), the Toxic Substances Control Act 
(TSCA) regulates domestic manufacturing and importation of chemical substances and 
mixtures. One group of chemicals that are exempted from this law is pesticides, which 
are regulated under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) (US 
Environmental Protection Agency, 2002a, 2008). However, as pesticides are designed to 
be biologically active and cause harm to insects, plants or other living things, laws 
regulating pesticides are much stricter than those regulating industrial chemicals. 
Originally enacted in 1947, FIFRA calls for the Environmental Protection Agency (EPA) 
to ensure that a registered pesticide will not have “unreasonable adverse effects on 
humans and the environment” (Lolley, 1990). To register a pesticide, the registrant is 
required to conduct many studies to assess the safety of the chemical, and the EPA is left 
to determine whether the pesticide meets the safety standard. Since its establishment this 
law has undergone many amendments, and as a result of the Food Quality Protection Act 
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of 1996, pesticides are under continuous review by the EPA and go through a 
reregistration process every 15 years. This ensures that, if new concerns are raised due to 
recently published data, the pesticide will get reevaluated for use (Lolley, 1990). TSCA, 
on the other hand, was written in 1976, and approximately 62,000 chemicals in 
commerce were “grandfathered” under this law. Under TSCA, these chemicals are 
considered “existing” chemicals, which can remain in commerce unless the EPA is able 
to demonstrate a potential for hazard. In other words, these “existing” chemicals are 
presumed “safe” until there is reason to believe they are dangerous. “New” chemicals 
under TSCA are those that are being introduced into commerce for the first time, or 
existing chemicals that are being registered for a new use. For new chemicals, EPA relies 
on the manufacturer to test the chemical, and, though the responsibility to determine 
whether the chemical poses a human or environmental health risk is on the manufacturer, 
there are no specific toxicity testing requirements (Locke and Myers, 2010). Therefore, 
even today, the majority of chemicals on the TSCA Inventory, which is now over 84,000, 
still have not been assessed for potential health and/or environmental impacts. 
 The increase in global chemical production is, to some degree, driven by the 
redistribution of chemical production in markets around the world. Due in part to the 
economic recession in 2007 and its larger impact on developed countries, developing 
countries have begun to emerge as leaders in the chemical industry. While the European 
Union (EU) and North American Free Trade Agreement (NAFTA) countries reported 18 
and 17% of total global chemical sales in 2012, over 50% of the total world chemical 
sales were from Asia. China alone accounted for over 30% of these chemical sales, and 
chemical production in the rest of Asia is on the rise as well (European Chemical 
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Industry Council, 2014; Volz and Elliott, 2013). Currently, the only chemicals in 
commerce regulated under TSCA include the final chemical-containing products that are 
imported into the United States, as well as domestically manufactured chemicals. This 
means that potential risks within these developing countries where chemical production 
occurs are not considered, and in most cases, regulations on basic chemical safety within 
these countries are less stringent and unenforced, providing an unfair risk for these 
disadvantaged populations (Volz and Elliott, 2013). In addition, there are a handful of US 
chemical companies attempting to maintain their competitive advantage by shifting their 
chemical production to Asia and Latin America, expanding their global strategies 
(KPMG International, 2010). Therefore, there is a recognized need to balance risk to 
account for inconsistent standards in regulations from industrialized to developing 
countries.  
 This continuous rise in chemical production and sales and redistribution 
creates much concern about the minimal amount of safety data available for these 
chemicals. In addition to variation in written regulations for registering industrial 
chemicals vs. pesticides within the US, this has drawn a lot of attention to the current 
state of TSCA. In 2007, the EU implemented the Registration, Evaluation, Authorisation, 
and Restriction of Chemicals (REACH) Regulation for management of chemicals in 
commerce, which made it a requirement for safety data to be submitted for new and 
existing chemicals produced in or imported into the EU (Vogel and Roberts, 2011). As 
there is no distinction between new and existing chemicals under this law, all chemicals 
produced or imported in “sufficient” quantities (at least 1 metric ton/year) have to be 
assessed for health and safety by 2018 (Egeghy et al., 2011; Kvinge, 2011). This 
 4 
regulation shifts the responsibility of data generation and risk assessment for all 
chemicals to industry rather than government authorities. The implementation of REACH 
in the EU has created many initiatives for moving forward with reform of the TSCA. 
Although two bipartisan bills have been proposed, one from the Senate (Chemical Safety 
Improvement Act) and one from the House of Representatives (Chemicals in Commerce 
Act), there is a lot of controversy over the amendment of the TSCA bill (Locke and 
Myers, 2011). Ideally, a new federal statute would require evaluations for all chemicals in 
active commerce and allow EPA to require safety testing without having to show 
potential hazard prior to issuing a testing request. Generating toxicity data for the 84,000 
chemicals regulated under the TSCA is not only a huge burden for the EPA, but it is also 
very costly and impractical to generate toxicity data using traditional methods, such as 
those used for the FIFRA, to determine risk for these chemicals (Locke and Myers, 
2010). 
 
1.2 HUMAN HEALTH RISK ASSESSMENT 
 Within the current framework used primarily for chemicals regulated under 
FIFRA, risk assessment comprises three main components: hazard identification, 
exposure assessment, and risk characterization. Within hazard identification, animal 
bioassays are used to identify the potential harmful effects of a contaminant. Toxicity 
tests conducted during the hazard identification process are divided into two main types: 
non-cancer and cancer. Currently, non-cancer endpoint hazard identification toxicity tests 
rely primarily on conventional animal bioassays that use rodent models. The required 
toxicity tests include various acute, subchronic, and chronic studies that assess oral, 
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dermal, and inhalation toxicity, eye and dermal irritation, skin sensitization, and 
neurotoxicity. Prenatal developmental toxicity and reproduction and fertility effects also 
must be assessed, as well as metabolism, pharmacokinetics and immunotoxicity (Office 
of Chemical Safety & Pollution Prevention, 2013). After the initial data requirements are 
submitted to the EPA, a pesticide can be fully registered, conditionally registered, or 
rejected. If there is reason to believe that more toxicity testing is needed, a pesticide can 
be conditionally registered and more data may be solicited before full registration is 
considered (US Environmental Protection Agency, 2015).  
 During exposure assessment, health risks are predicted based on the 
frequency, magnitude, and duration of acute, sub-chronic, or chronic exposures. First, the 
intake or uptake of the chemical contaminant from contact with air, water, house dust, 
soil, or other sources is quantified, and then the internal or delivered dose of the parent 
chemical or metabolite at the target organ is predicted using pharmacokinetic models (US 
Environmental Protection Agency, 2012). To characterize risk, the no observed adverse 
effect level (NOAEL) endpoint from acute, sub-chronic, or chronic toxicity studies is 
used, and uncertainty, or safety factors, are applied to account for genetic variation in 
human-to-human extrapolation, animal-to-human extrapolation, and other factors to 
generate a reference dose (RfD). The RfD is then divided by the average daily dose 
(ADD) estimated for human exposure to determine the level of concern (%RfD) for a 
single contaminant or single exposure pathway. During risk characterization, an 
additional uncertainty factor is generally applied for infants and children to take into 
account potential differences in susceptibility such as pre- and post-natal toxicity. If the 
%RfD is greater than 100%, a chemical is considered to be a concern. However, because 
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of the assumptions made in using uncertainty factors, there is potential for the %RfD to 
be over or underestimated (US Environmental Protection Agency, 2002b). 
 
1.2.1 CURRENT REGULATORY TOXICITY TESTING PARADIGM 
 For decades, conventional toxicity tests that rely on mammalian models have been 
used to predict toxicity and for estimating risk. The major advantage of the traditional 
testing strategy is that there are known genetic and physiologic similarities between 
rodents and humans. Although ideally a combination of studies on animal and human 
models would provide the best and most informative data for assessing risk, most of the 
time it is difficult to obtain data for hazard assessment of specific chemicals in humans. 
In addition, human exposure information may be limited and unknown environmental 
factors may cause uncertainties (US Environmental Protection Agency, 1998). The 
availability of different rodent strains allows for genetic variation in susceptibility to be 
accounted for; however, this also generates concern about which strain is the most 
appropriate for testing a broad range of chemicals. 
Unfortunately, the current toxicity testing paradigm is unable to provide 
information for a large number of chemicals in commerce.  For example, only five 
industrial compounds have been listed as developmental neurotoxicants: lead, 
methylmercury, polychlorinated biphenyls, arsenic, and toluene (Grandjean and 
Landrigan, 2014), suggesting that either the current traditional testing strategy is effective 
at keeping harmful chemicals out of commerce or, more likely, the potential toxicity of 
the majority of industrial compounds on the developing nervous system has not been 
adequately characterized or tested at all (Knudsen et al., 2011). Although the use of 
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traditional toxicity tests is advantageous in some ways, the drawbacks far outweigh the 
advantages – it is costly, time- and resource-intensive, low-throughput, does not allow for 
various life stages to be tested, and generally relies on a crude endpoint that does not 
allow mechanisms of toxicity to be explored. Due to these drawbacks and the high 
demand to obtain toxicity data for thousands of chemicals in commerce regulated under 
TSCA, there has recently been a push for a “new normal” for toxicity testing, shifting the 
paradigm to using computational toxicology, cell-free and cell-based assays, and non-
mammalian animal models for screening and prioritizing chemicals for testing in rodent 
models. There has been a recognized need for the development of rapid and cost-effective 
high-content and high-throughput screening (HCS/HTS) assays that use small non-
mammalian animal models such as zebrafish to help efficiently screen and prioritize these 
chemicals for more low-throughput toxicity testing. The advantages of HCS/HTS assays 
compared to low-throughput assays are that they often times contain much larger sample 
sizes and require little technical material. These types of assays can be designed to not 
only assess morphological endpoints, but also multiple functional endpoints, providing 
detailed information on how a chemical affects survival and body size, as well as give 
insight into the potential mode of action (Leet et al., 2014; Yozzo et al., 2013). 
Information gained from these studies can help identify the most important endpoints of 
interest for mammalian studies as well as the chemical concentrations to use. 
 
1.3 DEVELOPMENTAL NEUROTOXICITY (DNT) 
In today’s world, more than 96% of manufactured consumer goods and products 
are directly tied to the US chemical industry (American Chemistry Council, 2014). It is 
 8 
well known that the general population is exposed to many chemicals throughout their 
lifetime, including potentially neurotoxic chemicals (US Environmental Protection 
Agency, 1998). In recent years, an increase in the prevalence of neurodevelopmental 
disorders, such as autism, attention-deficient hyperactivity disorder, dyslexia, and others, 
has lead to a growing interest in the potential risks of neurotoxic chemical exposure 
during early life-stages and the resulting effects on human health (US Environmental 
Protection Agency, 1998). Although a percentage of these can be attributed to genetic 
factors (30-40%), it is suspected that social and environmental factors are also involved.  
In fact, evidence has demonstrated that an increased risk of attention-deficient 
hyperactivity disorder has been linked to prenatal exposures to manganese, 
organophosphate insecticides, and phthalates in drinking water, and an increased risk of 
autism spectrum disorder has been linked to air pollution in California (Grandjean and 
Landrigan, 2014). 
Developmental neurotoxicity is defined as exposure to a chemical, physical, or 
biological agent that occurs during development and results in an adverse change in the 
structure or function of the central and/or peripheral nervous system (Giordano and 
Costa, 2012). It is well known that the developing nervous system is a sensitive target for 
chemicals in both human and animal models (Giordano and Costa, 2012; Grandjean and 
Landrigan, 2006). Early life-stage exposures have the potential to result in alterations in 
brain development and maturation, causing irreversible functional effects early on or in 
later life stages (Grandjean and Landrigan, 2014; Jacobson-Kram, 2001). Throughout 
development, the fetus is not well protected from exposure to environmental toxicants. 
Detoxifying mechanisms are not completely functional, chemicals can cross the placenta 
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into the bloodstream, and the blood-brain barrier is not completely formed in the early 
stages, providing only partial protection (US Environmental Protection Agency, 1998). 
Levels of exposure much lower than the concentrations known to adversely affect adults 
may cause permanent damage in the brain during early development (Grandjean and 
Landrigan, 2014; Jacobson-Kram, 2001). 
One well-known chemical that has been shown to cause DNT in children at much 
lower levels than the levels that cause neurotoxicity in adults is lead. Lead was first used 
in paints in the 1800s, and then in gasoline beginning in the 1920s (Giordano and Costa, 
2012). In adult humans, lead exposure primarily occurs within the workplace, and the 
most common resulting clinical effect is peripheral neuropathy, which occurs when lead 
levels in blood are approximately 60 µg/ml. However, this effect is reversible using 
chelation therapy. At higher lead concentrations in the blood (100 µg/ml), colic, 
paralysis, serious motor effects, and, in severe cases, brain disorders, can occur 
(Giordano and Costa, 2012; Needleman, 2004). In the 1970s, the maximum acceptable 
blood level for lead in children was 60 µg/dl, as it was based on the level associated with 
clinical signs of toxicity in adults. Although the first described case of lead poisoning in 
children in the US was in 1914, it wasn’t until the 1970s that a better understanding of the 
developmental neurotoxic effects of lead became apparent. During this time, a handful of 
major epidemiological studies began to show associations between body burden of lead 
in children and lower academic performance and shortened attention span, in the absence 
of clinical signs of acute toxicity. These data lead to regulatory changes, including 
lowering the level of concern in children from 60 µg/dl to 10 µg/dl and the phasing out of 
lead gasoline and paint. By 1991, blood levels of lead in children had dropped 
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significantly. Even so, in the absence of signs of acute toxicity, associations between 
blood lead levels of 2 µg/ml and decreased academic performance and other behavioral 
effects have still been observed (Giordano and Costa, 2012). Similar behavioral 
alterations, cognitive defects and impaired learning abilities have also been observed in 
animals such as rodents and primates (Needleman, 2004).  
 
1.3.1 HISTORY OF THE DNT GUIDELINE 
In addition to lead, methylmercury was also recognized as a developmental 
neurotoxicant in the mid-1950s when children of mothers living around Minamata Bay 
who consumed methylmercury-contaminated fish were found to exhibit neurological 
deficits (Giordano and Costa, 2012). In subsequent years, there were more than 500 
registered pesticides with varying active ingredients and potencies, the majority of which 
targeted the nervous system of insects. It was also estimated that 3-28% of all chemicals 
were thought to have neurotoxic potential (US Environmental Protection Agency, 1998). 
In the early 1960’s, publications that examined the effect of chemicals on behavioral 
function in young and adult animal models began to emerge. During this time period, 
there were also more than 500 registered pesticides with varying active ingredients and 
potencies, the majority of which targeted the nervous system of insects. In addition, it 
was estimated that 3-28% of all chemicals were thought to have neurotoxic potential (US 
Environmental Protection Agency, 1998). The extensive evidence in the scientific 
literature evaluating chemical effects on the development and function of the nervous 
system provided a strong foundation for development of a DNT guideline. Collaborative 
studies within and across laboratories worldwide began to evaluate the validity, 
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reliability, and variability of these behavioral tests and, by 1986, a DNT guideline was 
established within the US for specific solvents. However, it wasn’t until 1991 that this 
guideline included evaluation of toxic substances and pesticides. In 1998, the US EPA 
DNT guideline was revised as part of an effort to harmonize guidelines within the US 
EPA and OECD. In 1995, an OECD Working Group recommended the development of 
OECD Test Guideline 426 (Developmental Neurotoxicity), and after multiple revisions, it 
was finalized in 2007 (Makris et al., 2009). 
 Test Guideline 426: Developmental Neurotoxicity (http://www.oecd-
ilibrary.org/environment/test-no-426-developmental-neurotoxicity-study_978926406739 
4-en) assesses the potential effects of pre- and postnatal chemical (mainly pesticide) 
exposure on the morphology and function of the developing nervous system within 
preweaning, adolescent, and young adult rodents (Organization for Economic Co-
operation and Development, 2007). This assay evaluates the potential for DNT using a 
series of physical and developmental landmarks and a range of functional/behavioral 
endpoints comprising motor activity (including habituation), motor and sensory function, 
and cognitive function (learning and memory) (Organization for Economic Co-operation 
and Development, 2007). Commonly used strains of rats are preferred for the DNT 
guideline, and a minimum of 20 litters per treatment group and 3-4 dose levels plus a 
vehicle control are needed for successful study completion. Therefore, assuming an 
average litter size of 8-12 pups, each DNT study requires 640 to 1200 rats (excluding 
dams) per chemical. Exposure of pregnant female rats to a chemical occurs at minimum 
from gestation day (GD) 6 (implantation) through lactation (post-natal day (PND) 21), 
and DNT tests are conducted on the offspring periodically from about PND 4 (sometimes 
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earlier) through PND 60-70 to assess select endpoints within young adult rats 
(Organization for Economic Co-operation and Development, 2007). This test, although 
not routinely required by regulatory agencies in the US, is required if other information 
indicates the potential for DNT. According to the EPA, this toxicity test must be 
completed using a weight of evidence approach if “the pesticide (i) causes treatment-
related neurological effects in adult animal studies, (ii) causes treatment-related 
neurological effects in developing animals, following pre- and postnatal exposure, (iii) 
elicits a causative association between exposures and adverse neurological effects in 
human epidemiological studies, (iv) evokes a mechanism that is associated with adverse 
effects on the development of the nervous system” (US Government Publishing Office 
and Office of the Federal Register, 2012). 
Recent evidence suggesting an association between neurodevelopmental disorders 
and chemical exposure emphasizes the lack of DNT data available for chemicals 
regulated under TSCA, as it is estimated that only about 200 (2%) of the 84,000 
chemicals on the TSCA Inventory have undergone DNT testing (Giordano and Costa, 
2012). In addition, it is has been shown that DNT studies can provide information about 
sensitive neurobehavioral endpoints in offspring that are not examined in any other 
required test guideline, highlighting its value as a sensitive endpoint and usefulness as a 
valuable source of data for risk assessment (Makris et al., 2009). However, it is 
impractical to use the existing DNT test guideline to test these chemicals, as this test is 
costly, time-intensive, and low-throughput. For a single chemical, this test can take up to 
one year and cost $1 million. Due to these costs and a lack of regulatory demand, only 
about 90 chemicals have been tested in the last decade (Crofton et al., 2012). Although 
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significant advancements in assays that use alternative non-mammalian models have 
occurred over the last 5-10 years, a large majority of assays relevant to DNT are focused 
on key molecular and cellular events in vitro and, as such, do not address the potential for 
chemically-induced DNT within an intact organism (Coecke et al., 2007; Crofton et al., 
2011). Therefore, there is a recognized need to use alternative non-mammalian models to 
support screening and prioritization of chemicals for DNT testing and to help uncover 
mechanisms of DNT for pesticides and understudied high-production volume chemicals 
in commerce (Coecke et al., 2007; Crofton et al., 2011).  
 
1.4 ZEBRAFISH AS A MODEL FOR EARLY NEURODEVELOPMENT 
Zebrafish have been used as a model to study vertebrate neurodevelopment for 
over 30 years (Eisen et al., 1989; Westerfield et al., 1990), and, as a result, the nervous 
system circuitry within zebrafish is well characterized and understood (Myers, 1986; 
Westerfield, 1986). Neural tube formation and central nervous system development in 
zebrafish occurs during the segmentation period (10−24 hours-post-fertilization (hpf)) 
(Kimmel et al., 1995). By 18 hpf (18-somite stage), the anterior neural tube develops into 
ten distinct brain neuromeres while the posterior neural tube develops into the spinal cord 
(Kimmel et al., 1995). Primary interneurons differentiate and extend their axons in a 
relatively simple pattern within each brain neuromere and spinal cord segment. 
Throughout development, neurons within the spinal cord are continually integrated into a 
functional network of circuits, producing a series of locomotive behaviors (Knogler et al., 
2014). Primary motoneurons, although born during late gastrulation (9-10 hpf), begin to 
extend their axons from the spinal cord around 18 hpf, innervating target axial muscles in 
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a highly stereotyped, error-free manner (Myers, 1986). This results in the initiation of 
weak, spontaneous muscle contractions within the developing embryo (Kimmel et al., 
1995). This spontaneous behavior can be classified into two groups: single coils and 
double coils (Knogler et al., 2014). The initial spontaneous contractions consist of single 
coils, where, after a single contraction of the trunk, the tail returns to its resting position. 
Double coils begin about six hours after single coils and consist of two contralateral 
contractions of the trunk within one second. Two other locomotive behaviors also occur 
sequentially within zebrafish during development – touch-evoked coils, which begin at 
21 hpf and organized swimming, which begins at 27 hpf (Saint-Amant and Drapeau, 
1998). By 24 hpf, the nervous system is fully functional, allowing for rapid assessment of 
neurotoxicity using these neurobehavioral endpoints within less than 30 hours after 
exposure initiation. 
Zebrafish embryogenesis occurs rapidly, ex utero and consists of seven well-
documented developmental stages: zygote (0-0.75 hpf), cleavage (0.75-2.25 hpf), blastula 
(2.25-5.25 hpf), gastrula (5.25-10 hpf), segmentation (10-24 hpf), pharyngula (24-48 
hpf), and hatching (48-72 hpf) (Kimmel et al., 1995). Due to the small size and 
transparency of zebrafish during embryogenesis, the potential for adverse effects on the 
developing nervous system can be readily evaluated at both the morphologic- and 
functional-level. For instance, the notochord, spinal cord, or brain can be imaged in vivo, 
and locomotive behaviors – indicators of effects on the nervous system – can be assessed 
within 96- or 384-well plates (Lee and Freeman, 2014). Females produce hundreds to 
thousands of embryos providing a large sample size, which is especially beneficial for 
HCS/HTS assays. The zebrafish genome is fully sequenced, and approximately 70% of 
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human genes have at least one zebrafish orthologue (Howe et al., 2013). Furthermore, 
orthologous genes with key regulatory roles in neural development are also functionally 
conserved; therefore, neurotoxic chemicals that affect zebrafish neural development are 
likely to also affect human neural development. Established transgenic lines can be used 
for live imaging of the nervous system, and immunohistochemistry techniques can be 
used to label neurons and axons within developing zebrafish embryos (Higashijima et al., 
2000; Trevarrow et al., 1990). Moreover, compared with other larger vertebrate models 
like rodents, the costs associated with start-up and maintenance of zebrafish colonies are 
minimal and requires significantly less personnel labor and laboratory space. Due to these 
advantages, zebrafish have emerged as an in vivo alternative non-mammalian model for 
DNT testing to help screen and prioritize chemicals for rodent assays (Lee and Freeman, 
2014). In fact, zebrafish have become a popular vertebrate model for studying the 
developmental basis of human diseases such as autism, schizophrenia and others (Morris, 
2009; Tropepe and Sive, 2003).   
 
1.4.2 THE NEED FOR DNT-SPECIFIC HCS/HTS ASSAYS  
Several zebrafish-based DNT studies have relied on neurobehavioral alterations 
as a neurotoxicological endpoint. For example, locomotion assays using zebrafish have 
been used to examine spontaneous tail contractions, touch-response, and/or swimming 
patterns in response to chemical and/or light stimuli in microplate format (Irons et al., 
2010; Kokel et al., 2010; Stanley et al., 2009). One study also demonstrated that 
behavioral alterations after exposure to a set of ten compounds including known 
developmental neurotoxicants were comparable to existing mammalian data (90% 
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agreement overall), supporting the use of early life-stage zebrafish to predict chemically-
induced DNT within higher organisms (Selderslaghs et al., 2013). Although valuable for 
providing information on behavioral responses following developmental exposure, these 
assays can be complex, requiring treatment solution renewals (and, therefore, more 
technical material), excessive embryo/larval handling, and cost-prohibitive infrared 
cameras needed for imaging under dark conditions. Moreover, conventional zebrafish-
based locomotive assays are conducted using a larval stage (6-7 days post-fertilization 
(dpf)) that is protected by animal use regulations around the world, likely resulting in 
minimal animal use reductions for DNT testing (Irons et al., 2009; Padilla et al., 2011).  
In recent years, there has been some discontinuity in toxicity results present 
among current zebrafish studies, which is likely due to variations in test methods across 
different laboratories due to complex experimental designs. Therefore, despite significant 
advancements in zebrafish locomotion assays, rapid and streamlined HCS assays are still 
needed to facilitate screening and prioritization of chemicals for DNT testing within 
rodents. More simplified, efficient toxicity tests would improve the variation observed in 
test results across academic labs, and provide a uniform way to screen compounds with 
consistent results. Therefore, this dissertation is focused on using spontaneous tail 
contractions – the first sign of locomotion in zebrafish embryos – as a rapid, cost-
effective endpoint amenable for identification of potential developmental neurotoxicants. 
 
1.5 RESEARCH OBJECTIVES 
 As discussed above, there is a need to predict the potential for DNT for 
thousands of untested chemicals used in commerce without using conventional animal 
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bioassays. Alternative animal models can provide a rapid, cost-effective alternative 
method for screening and prioritizing chemicals for resting in rodents, as well as 
identifying the molecular mechanisms of neurotoxicity for these chemicals. Using 
zebrafish embryos as a model for studying the developing nervous system, the first part 
of this dissertation (Chapter 2) focuses on developing a 384-well-based HCS assay for 
identification of potential developmental neurotoxicants using spontaneous activity as a 
behavioral readout. Subsequently, the second part (Chapter 3) aims to begin investigating 
the mechanism of action of abamectin – a potent avermectin insecticide identified as a 
positive hit in the HCS assay described within Chapter 2 – within zebrafish embryos.
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CHAPTER 2
HIGH-CONTENT SCREENING ASSAY FOR IDENTIFICATION OF CHEMICALS IMPACTING 
SPONTANEOUS ACTIVITY IN ZEBRAFISH EMBRYOS 
2.1 INTRODUCTION 
In addition to animal use considerations, it is impractical to screen the thousands 
of untested chemicals in commerce using the existing DNT test guideline, as this test is 
costly, time-intensive, and low-throughput. Furthermore, in recent years, there has been 
an increase in the number of emerging contaminants of concern, such as pharmaceutical 
and personal care products and nanomaterials, most of which have not been adequately 
tested for potential toxic effects. Rapid and streamlined HCS assays that rely on 
locomotor endpoints are needed to facilitate screening and prioritization of chemicals for 
DNT testing within rodents. Therefore, for this study, we focused on spontaneous tail 
contractions – the first sign of motor activity – within zebrafish embryos as a behavioral 
endpoint amenable for identification of potential developmental neurotoxicants. Although 
other assays (Kokel et al., 2010; Truong et al., 2013) have focused on this endpoint, the 
HCS assay reported here provides a streamlined discovery platform with 1) increased 
sample sizes; 2) broad concentration-response format; 3) short assay duration (~22 hours 
total); and 4) minimal technical-grade test material needed for screening. 
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2.2 MATERIALS AND METHODS 
2.2.1 ANIMALS 
For this assay, we relied on a robust line of transgenic zebrafish (fli1:egfp) that 
stably express enhanced green fluorescent protein (eGFP) within vascular endothelial 
cells (Lawson and Weinstein, 2002). This strain begins expressing eGFP at ~14 hours 
post-fertilization (hpf), allowing us to accurately track spontaneous tail contractions in 
the absence of shading effects observed under transmitted light. Adult fli1:egfp zebrafish 
were maintained on a 14-h:10-h light:dark cycle within a Mini Mass Embryo Production 
System (mini-MEPS) (Aquatic Habitats, Inc., Apopka, FL) containing a photoperiod light 
cycle dome and recirculating conditioned reverse osmosis (RO) water (~27-28°C). Adult 
females and males were bred either directly within the mini-MEPS, directly on-system 
using in-tank breeding traps suspended within 3 L tanks, or off-system within a light- and 
temperature-controlled incubator using breeding traps suspended within 1 L tanks. For all 
experiments described below, newly fertilized eggs were staged according to previously 
described methods (Kimmel et al., 1995). All fish were handled and treated in accordance 
with approved Institutional Animal Care and Use Committee (IACUC) protocols at the 
University of South Carolina – Columbia.   
 
2.2.2 CHEMICALS 
Chemicals were purchased from ChemService, Inc. (West Chester, PA) and 
Sigma Aldrich (St. Louis, MO). Chemical names, chemical formulas, CAS registry 
numbers, vendor, and purities are provided within Table A.1. Within 24 hours of test 
initiation, stock solutions of each chemical were prepared by dissolving chemicals in high 
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performance liquid chromatography (HPLC)-grade dimethyl sulfoxide (DMSO) (50 
mM), and then performing two-fold serial dilutions into DMSO to create stock solutions 
for each working solution. All stock solutions were stored at room temperature within 2 
mL amber glass vials containing polytetrafluoroethylene (PTFE)-lined caps. For each 
individual plate, working solutions of all treatments were freshly prepared by spiking 
stock solutions into embryo media (EM) (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 
0.33 mM MgSO4), resulting in 0.1% DMSO within all vehicle control and treatment 
groups. 
 
2.2.3 HIGH-CONTENT SCREENING (HCS) ASSAY 
Exposure setup. Black 384-well microplates containing 0.17-mm glass-bottom 
wells (Matrical Bioscience, Spokane, WA) were used for this assay. Newly fertilized 
eggs were collected immediately after spawning and placed in groups of approximately 
50 per glass petri dish within a light- and temperature-controlled incubator until 5 hpf. 
Although dechorionation may help decrease uncertainties regarding uptake across the 
chorion, previous attempts within our laboratory to dechorionate embryos prior to 
exposure resulted in unacceptable survival within control embryos; therefore, chorionated 
embryos were used for all exposures. Vehicle control (0.1% DMSO) or treatment 
solution (50 µL per well) was added to odd columns of a 384-well plate at 5 hpf. Using 
clean forceps, 192 viable fli1:egfp embryos were then manually arrayed into the plate 
over a 20-minute time period, resulting in one embryo per well and 16 initial embryos per 
column. Each plate was checked to ensure that all embryos were intact or undamaged 
following loading. Initial attempts to use 384 embryos were unsuccessful due to 
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increased imaging duration, resulting in variation in spontaneous activity within vehicle 
control embryos across the plate (Figure A.1). For chemical screening assays, vehicle 
control groups occupied two columns flanking the left and right sides of the plate 
(columns 1 and 23) to account for potential control variance in spontaneous activity from 
initiation to termination of image acquisition. The plate was then incubated at 28°C under 
a 14-h:10-h light:dark cycle and static conditions until 24 hpf.  
Image acquisition. At 24 hpf, the plate was removed from the incubator and 
allowed to acclimate in a second incubator at 25ºC in treatment solution for 1 hour with 
the lid removed. This acclimation was done to ensure that changes in temperature from 
the incubator (28°C) to the imager (25°C) did not affect spontaneous activity, as previous 
experiments have demonstrated that temperature alterations can affect this behavior 
(Saint-Amant and Drapeau, 1998). The plate was then centrifuged for 3 minutes at 200 
rpm to ensure that the majority of embryos were near the bottom of each well. Using an 
automated image acquisition protocol (Figure 2.1) and parameters (Table A.2) optimized 
for our ImageXpress® Micro (IXM) Widefield High-Content Screening System 
(Molecular Devices, Sunnyvale, CA), each embryo was imaged in treatment solution 
over a 6-second time period to assess the presence or absence of spontaneous tail 
contractions. Image acquisition began within five to ten minutes after centrifugation, 
commencing at well A01 and proceeding down each column across the plate from 
column 1 to column 23. Throughout this process, one 6-second stream was acquired at a 
time for each well. This time period was chosen to minimize variation in spontaneous 
activity across the plate due to increased imaging duration. Image acquisition procedures 
were identical for each independent plate. During the entire ~1.4-hour image acquisition 
 22 
period, internal temperature within the IXM system was maintained between 25-27°C by 
removing panels on both sides of the IXM system and blowing air from left to right 
through the IXM with a portable fan; internal temperature was monitored and recorded at 
initiation and termination of imaging using a digital thermometer.  In accordance with 
National Institutes of Health (NIH) guidelines (National Institutes of Health, 2013), 
embryos were then euthanized by placing the plate at -20ºC.  
 Data extraction. Custom journal scripts for video generation were developed 
using MetaXpress® 4.0.0.24 software (Molecular Devices, Sunnyvale, CA). Prior to data 
extraction, stream acquisitions within each well were inspected within MetaXpress to 
assess survival. As heart morphogenesis is not complete until ~48 hpf, presence or 
absence of heartbeat was not used as a criterion for survival. Rather, coagulated embryos 
and embryos with undeveloped or absent tails were considered dead and were not 
analyzed for total body area or spontaneous activity. Fully automated journal scripts were 
used to generate videos of each well by converting each stream acquisition to an .AVI 
file. Video file sizes were reduced within Format Factory (http://www.pcfreetime.com/) 
by conversion to MPEG4 (DivX). Converted videos were then imported into EthoVision 
XT 9.0 (Noldus Information Technology, Leesburg, VA) to determine the mobility state 
of each embryo. Based on user-defined detection settings that identify the embryo as the 
subject, embryos were considered highly mobile (exhibiting spontaneous tail 
contractions) if the change in subject pixel area from one frame to another was above a 
previously optimized user-defined threshold. Initial attempts to use EthoVision to 
quantitatively assess the number of spontaneous tail contractions were unsuccessful due 
to variation in this behavioral phenotype within individual control embryos (Figure A.3). 
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Rather, EthoVision output was used to assign spontaneous activity values to each 
embryo. Inactive embryos were defined as embryos that were immobile during the entire 
6-second stream acquisition and were assigned an activity value of 0. Active embryos 
were defined as embryos that moved for at least 0.1 second and were assigned an activity 
value of 1. Within EthoVision, duration is assessed in 0.1-second increments; therefore, 
we used this value as a criterion for activity in order to include embryos exhibiting partial 
tail contractions as active embryos.  
Automated custom journal scripts within MetaXpress® were used to analyze total 
embryo body area in order to 1) reliably identify treatment-related effects and 2) focus 
our analyses on targeted impacts on spontaneous activity in the absence of significant 
effects on embryonic growth. Treatments resulting in a significant decrease in total body 
area were not analyzed for spontaneous activity. Embryos exhibiting notochord 
malformations that were not detected by analysis of total body area were also excluded 
from analysis of spontaneous activity. Additional information about parameters used in 
EthoVision XT 9.0 is provided in Table A.3. Additional details about the data extraction 
and analysis process are provided in Figure A.2. 
 
2.2.4 STATISTICAL ANALYSIS 
All statistical procedures were performed using SPSS Statistics 20.0 (Chicago, 
IL). Non-parametric tests were used for analyzing spontaneous activity data, as these data 
were categorical and did not meet normality assumptions. A Kruskal-Wallis test was used 
(α = 0.05) to test for main effect of treatment, and Mann-Whitney pair-wise comparisons 
were used to test for differences between vehicle control columns 1 and 23 and treatment 
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columns relative to vehicle control columns (α = 0.05). For chemical screening assays, 
treatments were only considered significant if different from both control columns. For 
total body area analysis, a general linear model (GLM) analysis of variance (ANOVA) (α 
= 0.05) was used, as these data did not meet the equal variance assumption for non-GLM 
ANOVAs. Pair-wise Tukey-based multiple comparisons of least square means were 
performed to identify significant treatment-related effects. To estimate the median lethal 
concentration (LC50) after static exposure to each chemical from 5 to 25 hpf, a four-
parameter concentration-response curve was fit to percent mortality data using log-




2.3.1 HCS ASSAY VARIABILITY  
To determine assay variability, we imaged three independent control plates 
containing embryos incubated in EM at 28ºC from 5-24 hpf, and then acclimated for 1 
hour at 25ºC prior to imaging. Parameters provided in Figure A.2 and Tables A.2 and A.3 
were used to analyze total body area and spontaneous activity for each control plate. 
Percent survival and image success rates for each plate were consistently above 95% and 
99.5%, respectively (Table 1 and Figure 2.2A). When summarized by column, survival 
ranged from 87.5-100%, while image success rates ranged from 93.3-100% (Table A.4). 
While total body area was consistent within and across control plates (Figure 2.2B), 
spontaneous activity within and across control plates was variable, with an average 
percent by column ranging from 36.3-63.4% across all three plates (Figure 2.2C).   
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Based on performance within control plates, we then developed decision criteria 
for assay success (Figure 2.3). The percent of embryos with spontaneous activity per 
column ranged from 18.75% to 75% across all three plates (36 columns total), with the 
majority of columns ranging from 25 to 74% (Figure A.4). Therefore, based on these 
data, we concluded that spontaneous activity within each control group (columns 1 and 
23 for chemical screening assays) must be >18% in order to be considered a successful 
plate (Figure 2.3). Additionally, spontaneous activity within columns 1 and 23 must not 
be significantly different (p>0.05) from each other based on a Mann-Whitney test. If both 
criteria were met, the entire plate was then analyzed for total body area and spontaneous 
activity (Figure 2.3).   
 
3.3.2 HCS ASSAY REPRODUCIBILITY 
Based on previously published data, nicotine and paraoxon were selected as 
reference chemicals to evaluate assay reproducibility (Thomas et al., 2009; Yozzo et al., 
2013). Nicotine exposure resulted in no effect on survival, total body area, or 
spontaneous activity (Figure A.5). However, in the absence of an effect on survival and 
total body area at all concentrations tested, paraoxon exposure resulted in a 
concentration-dependent decrease in the percent of embryos with spontaneous activity at 
12.5, 25, and 50 µM (Figure 2.4). Based on this concentration-response test, three 
reference plates containing 96 initial embryos per treatment were then exposed to vehicle 
or 25 µM paraoxon. Percent survival, total body area, and image success rates of 
paraoxon-treated embryos were similar to vehicle controls (Figure 2.5 and Table 2), and 
the hypoactive effect of paraoxon on spontaneous activity was reproducible within and 
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across all three reference plates (Figure 2.5). Based on results of control and reference 
chemical plates, we concluded that this assay is reproducible based on sample sizes of 16 
initial embryos per column. 
 
3.3.3 CHEMICAL SCREENING 
Following assay development and optimization, we tested a small chemical 
library to evaluate the potential utility of this HCS assay for screening and prioritizing 
chemicals for DNT testing. Based on data available from previous teratogenesis screens 
using zebrafish embryos (Padilla et al., 2012), acute toxicity benchmarks (AC50) for 
chemicals within the U.S. Environmental Protection Agency’s (EPA’s) ToxCast™ 
Phase-I chemical library were ranked from most to least potent based on survival and 
gross malformations present at 6 dpf following a 8-hpf to 5-dpf exposure.  Using 
protocols described in Figure A.2, the most potent 18 chemicals (Table A.1, excluding 
nicotine and paraoxon) were selected to evaluate the ability of this assay to detect 
targeted effects on spontaneous tail contractions. Two chemicals (tefluthrin and 
milbemectin) were not commercially available (as of August 2013), and fentin was 
insoluble in DMSO at concentrations as low as 2.5 mM. Therefore, these three chemicals 
were not included in the final screen, resulting in a total of 15 chemicals tested in 
concentration-response format.  
A summary of statistical results and overall effects on spontaneous activity for all 
chemicals screened is provided within Table A.5. Of the chemicals tested, rotenone was 
the most acutely toxic based on survival and total body area, as 0.09 µM was the highest 
concentration analyzed due to a significant decrease in total body area at 0.19 µM and 
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0% survival in all other concentrations (Figure A.6). On the contrary, butafenacil, 
flumetralin, propargite, tribufos, and pyraflufen-ethyl showed no evidence of acute 
toxicity in this assay, with no effect on survival or total body area across all 
concentrations tested (0.09-50 µM) (Figures A.9, A.11, A. 13, A.16, A.19). 
Approximately one-third of the chemicals screened (thiram, fluthiacet-methyl, 
pyraclostrobin, (Z,E)-fenpyroximate, and trifloxystrobin) resulted in steep concentration-
response curves based on survival, where only a two-fold increase in concentration was 
required to decrease survival from >85% to 0% (Figures A.7, A.12, A.14, A.15, A.20).  
To determine the potential for DNT, spontaneous activity was assessed within 
treatment groups with >85% survival and no significant decrease in mean total body area 
relative to vehicle controls. Based on our chemical screen, we then compared the 
maximum tolerated concentration (MTC) for body area and spontaneous activity (Figure 
2.6).  Out of all 15 chemicals screened, exposure to abamectin – a widely used insecticide 
and chloride channel activator belonging to the avermectin class – resulted in a 
significant decrease in spontaneous activity at concentrations as low as 3.125 µM (Figure 
2.7). Based on these data, the entire ToxCast™ Phase-I chemical library was then 
searched for other commercially available avermectins to determine whether exposure to 
chemicals within the same class resulted in similar adverse effects on spontaneous 
activity. Based on this search, emamectin benzoate was screened, and, similar to 
abamectin, significantly decreased the percent of embryos with spontaneous activity (at 
25 and 50 µM) in the absence of effects on gross embryonic development, albeit with 




Although assays quantifying zebrafish locomotion have been developed, the HCS 
assay reported here provides a simpler discovery platform for identifying potential 
developmental neurotoxicants. Using 384-well plates, we were able to 1) increase sample 
size to 16 individual embryos per treatment (192 embryos total), 2) examine a broad 
concentration-response (vehicle control and 10 chemical concentrations), 3) decrease 
assay duration and volume of test material, and 4) identify chemicals that target the 
developing nervous system at non-teratogenic concentrations. After confirming assay 
variability and reproducibility using control plates and reference chemicals known to 
affect spontaneous activity, we then screened 16 chemicals within the U.S. EPA’s 
ToxCast™ Phase-I chemical library and found that exposure to abamectin and emamectin 
benzoate – both potent avermectins – abolished spontaneous activity in the absence of 
effects on survival and total body area.  
During embryonic development, spontaneous tail contractions occur due to 
innervation of primary motoneuron axons into target axial muscles in a highly 
stereotyped, error-free manner (Kimmel et al., 1995; Myers, 1986). This form of 
locomotion is controlled by neural networks within the spinal cord, as neither brain 
lesions nor isolation of the spinal cord from descending brain inputs affect this behavior 
(Downes and Granato, 2006). Although spontaneous activity has been suggested to occur 
in the absence of external cues such as touch (Brustein et al., 2003; Saint-Amant and 
Drapeau, 1998), there is evidence that spontaneous activity may be affected by high-
intensity light stimuli (Kokel et al., 2010). Despite controlling for developmental stage, 
temperature, and light conditions, we observed a high degree of natural variability in the 
 29 
percent of control embryos exhibiting spontaneous activity. We attempted to minimize 
this variation by loading two embryos per well and extending the imaging duration per 
embryo; however, these changes had no impact on minimizing variation of this 
behavioral phenotype. Therefore, since parameters were tightly controlled within our 
assay, the environmental or biological factors responsible for variation observed in our 
assay are currently unclear.  
Despite the natural variation in control spontaneous activity, our assay detected a 
significant decrease in spontaneous activity after exposure to paraoxon, and we 
demonstrated that this effect was reproducible across reference plates. However, contrary 
to previous studies in zebrafish (Thomas et al., 2009), nicotine did not affect spontaneous 
activity, a discrepancy that was likely due to differences in experimental design and 
exposure duration. In a study conducted by Thomas et al (2009), chorionated zebrafish 
embryos were incubated from fertilization to 23 hpf in 50-mm petri dishes and placed in 
groups of three embryos per dish. Embryos were then transferred to 30 µM nicotine for 
five minutes, and an increase in the number of spontaneous tail contractions was 
observed over this five-minute imaging period under transmitted light. In our assay, 
chorionated embryos were individually exposed to treatment solution from 5 to 25 hpf 
within single wells of a 384-well plate, and then imaged for six seconds each under 
fluorescence. Therefore, the absence of a nicotine-induced effect on spontaneous activity 
within our assay may be a result of different rearing conditions, extended exposure 
duration, decreased image acquisition duration, and/or the use of fluorescence rather than 
transmitted light.  
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Out of 16 ToxCast™ Phase-I chemicals screened, exposure to 14 of these 
chemicals resulted in no impact on spontaneous activity using this assay. Out of these 14 
chemicals, five chemicals had no impact on survival, total body area, or spontaneous 
activity up to 50 µM (the highest concentration tested), suggesting that these chemicals 
exhibited limited embryonic uptake – due to high rates of chemical absorption to 
microplate wells or low rates of chemical transport across the chorion – and/or negligible 
toxicity during this stage of development. However, exposure to nine out of these 14 
chemicals resulted in significant effects on survival or total body area at one or more 
concentrations yet did not affect spontaneous activity at non-teratogenic concentrations, 
suggesting that the primitive nervous system during this stage of development was not a 
target organ for these nine chemicals.  
Using this HCS assay, we discovered that exposure to abamectin and emamectin 
benzoate – both potent avermectins – significantly decreased spontaneous activity in the 
absence of effects on survival and total body area. Avermectins are primarily used for 
control of insects and helminthes (Taylor, 2001) and are thought to induce neurotoxicity 
by activation of either glutamate- or gamma aminobutyric acid (GABA)-gated chloride 
channels, interfering with signal transmission between nerve cells (Bloomquist, 1996; US 
Environmental Protection Agency, 2004). Although registered in the U.S. since the 1980s 
(US Environmental Protection Agency, 2004), to our knowledge very few studies have 
examined the neurotoxic effects of avermectin exposure on mammalian cells and model 
organisms, particularly during early development. In mouse neuroblastoma N2a cells, 
exposure to abamectin and doramectin resulted in a significant concentration-dependent 
inhibition of neurite growth (Sun et al., 2010). In zebrafish, semi-static exposure to 
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abamectin resulted in a decrease in swimming ability at 96-hpf (Tisler and Erzen, 2006). 
Most importantly, within a DNT study similar to OECD Test Guideline 426 
(Organization for Economic Co-operation and Development, 2007), exposure of mated 
female Sprague-Dawley rats to emamectin benzoate from gestation day 6 through 
lactation day 20 resulted in a dose-dependent decrease in motor activity in male and 
female offspring on postnatal day (PND) 17 but not PND 21; this decrease was also 
observed on PND 59 in females only (Wise et al., 1997). Therefore, based on our results 
and limited data available within the published literature, exposure to avermectins 
appears to result in disruption of nervous system function during early development.  
In summary, this HCS assay provides a streamlined platform with sufficient 
replication and exposure concentrations to screen and identify potential developmental 
neurotoxicants. Given that we relied on an embryonic stage (25 hpf) with a less 
developed nervous system compared to later larval stages (6-7 dpf), we recognize that our 
assay has the potential to be biased toward identifying chemicals with specific neurotoxic 
modes-of-action. However, compared to existing zebrafish-based locomotion assays 
conducted within 96-well plates (Padilla et al., 2011), this assay provides shorter 
exposure duration (1 day vs. 6 days) and decreased treatment solution volumes needed 
for screening (50 µL vs. 250 µL per well for static exposures). As a result, within a tiered 
testing framework, this assay has the potential for rapid, cost-effective prioritization of 
chemicals for DNT assays that rely on later stages of zebrafish and rodent development. 
Moreover, in the future this HCS assay can be readily coupled with reverse genetics 
approaches to identify the potential role of aberrant neurotransmitter signaling in 
chemically-induced effects on early neurodevelopment within zebrafish embryos. Over 
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the long-term, we envision that this HCS assay will help uncover mechanisms of DNT 
for pesticides and understudied high-production volume chemicals in commerce. 
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Table 2.1:  Image success rates for analysis of spontaneous activity and total body area 
within control 25-hpf zebrafish embryos across three independent plates containing an 
initial sample size of 192 embryos per plate. The percentage of live embryos was relative 
to an initial sample size of 192 embryos per plate, whereas the percentage of analyzed 
embryos was relative to the number of live embryos. 
 















1 192 100.0 192 100.0 192 100.0 
2 185 96.4 185 100.0 184 99.5 




Table 2.2:  Image success rates for analysis of spontaneous activity and total body area within reference chemical plates consisting of 
25-hpf zebrafish exposed to vehicle or 25 µM paraoxon across three independent plates containing an initial sample size of 96 
embryos per treatment per plate. The percentage of live embryos was relative to an initial sample size of 96 embryos per treatment per 
plate, whereas the percentage of analyzed embryos was relative to the number of live embryos. 
 
  Live Embryos Spontaneous Activity Total Body Area 












Vehicle (0.1% DMSO) 93 96.9 93 100.0 92 98.9 
25 µM Paraoxon 93 96.9 93 100.0 91 97.8 
2 
Vehicle (0.1% DMSO) 95 99.0 95 100.0 95 100.0 
25 µM Paraoxon 93 96.9 93 100.0 91 97.8 
3 
Vehicle (0.1% DMSO) 95 99.0 95 100.0 92 96.8 




Figure 2.1: Diagram summarizing the exposure setup, image acquisition, and data 
analysis endpoints for the HCS assay. Using automated image acquisition protocols and 
parameters optimized for our ImageXpress® Micro Widefield High-Content Screening 
System, each fli1:egfp embryo was imaged to assess the presence or absence of 





Figure 2.2: Survival (%) (A), total body area (µm2) (B), and spontaneous activity (%) 
(C) across three independent control plates consisting of 192 initial embryos per plate. 
Survival (%) and spontaneous activity (%) data are presented as mean ± SD across three 
independent plates. Total body area data are presented as mean ± SD across all embryos 
analyzed. N = final number of embryos analyzed. Numbers above each bar denote 





Figure 2.3: Decision tree for evaluation of assay success during exposure setup (Day 0), image acquisition (Day 1), and data 
extraction/analysis (Day 1). Criteria for control survival (>85% survival) and spontaneous activity were developed to (1) reliably 
identify treatment-related effects and (2) focus our analyses on targeted impacts on spontaneous activity in the absence of significant 





Figure 2.4: Paraoxon exposure results in a concentration dependent effect on 
spontaneous activity in the absence of effects on survival and total body area. Total body 
area data within each column are presented as mean ± SD. N = final number of embryos 
analyzed per column. Numbers above each bar denote percent spontaneous activity 
within that column. Asterisk denotes significant difference in percent spontaneous 




Figure 2.5: Survival (%) (A), total body area (µm2) (B), and spontaneous activity (%) 
(C) following exposure to vehicle (0.1% DMSO) or 25 µM paraoxon from 5 to 25 hpf in 
a 384-well plate containing 96 initial embryos per treatment per plate. Survival (%) and 
spontaneous activity (%) data are presented as mean ± SD across three independent 
plates. Total body area data are presented as mean ± SD across all embryos analyzed. N = 
final number of embryos analyzed across all three plates. Numbers above each bar denote 
percent spontaneous activity within that column. Asterisk denotes significant difference 




Figure 2.6: Comparison of the maximum tolerated concentration (MTC) for body area 
and spontaneous activity for 15 of the most acutely toxic ToxCast™ Phase-I chemicals 
screened using the HCS assay. Numbers above points denote the number of chemicals 





Figure 2.7: Abamectin exposure results in a concentration dependent effect on 
spontaneous activity in the absence of effects on survival and total body area. Total body 
area data within each column are presented as mean ± SD. N = final number of embryos 
analyzed per column. Numbers above each bar denote percent spontaneous activity 
within that column. Asterisk denotes significant difference in percent spontaneous 




Figure 2.8: Emamectin benzoate exposure resulted in a concentration dependent effect 
on spontaneous activity in the absence of effects on survival and total body area. Total 
body area data within each column are presented as mean ± SD. N = final number of 
embryos analyzed per column. Numbers above each bar denote percent spontaneous 
activity within that column. Asterisk denotes significant difference in percent 





ABAMECTIN INDUCES RAPID AND REVERSIBLE HYPOACTIVITY WITHIN EARLY  
  ZEBRAFISH EMBRYOS 
3.1 INTRODUCTION 
 Avermectins are naturally occurring 16-membered macrocyclic lactones produced 
as fermentation products by a soil-dwelling actinomycete bacterium (Streptomyces 
avermitilis) (Rugg, 2010). Isolated in the 1970s from a soil sample collected within 
Japan, these compounds have potent antihelminthic and antiparasitic properties (Rugg, 
2010), with a unique ability to act as “endectocides” on both ecto- and endoparasites 
(Omura and Crump, 2004). Although the mechanism of action is still not fully 
understood, avermectins are thought to induce neurotoxicity within invertebrates and 
vertebrates by direct activation or potentiation of glutamate- and/or γ-aminobutyric acid 
(GABA)-gated chloride channels, resulting in paralysis and eventually death 
(Bloomquist, 1996; Sanchez-Bayo, 2012). Despite uncertainties about the specific 
mechanism of action, the broad-spectrum activity of avermectins has led to widespread 
use for animal health and crop protection over the last 30 years. 
Avermectins consist of four related compounds (A1, A2, B1, B2), each containing a 
major (A1a, A2a, B1a, B2a) and minor (A1b, A2b, B1b, B2b) component (Clark et al., 1995; 
Jansson et al., 1996). As a synthetic derivative of avermectin B1 (or abamectin), 
ivermectin was the first commercially available avermectin introduced in 1981 as an 




used to treat onchocerciasis in humans, a disease commonly known as River Blindness 
(Campbell, 2012). In 1985, abamectin (80% B1a:20% B1b) was introduced as an 
agricultural insecticide and miticide in addition to use as a veterinary antiparasitic drug.  
As a result, abamectin is now registered worldwide for insect and mite control on crops 
such as citrus, nuts, ornamental plants, cotton, vegetables, strawberries, and grapes, as 
well as for control of fire ants (Dybas, 1989). From 1992 to 2005, only about 10,000 
pounds of abamectin per year were used in the United States (US), with the majority of 
use on orchards (almonds and oranges) and/or grapes within California, Florida, and 
Washington. However, following registration of abamectin as a seed treatment to control 
parasitic nematodes on cotton in 2006, use expanded throughout the Southeastern United 
States and into Texas, increasing to approximately 40,000-50,000 pounds per year from 
2006-2009 (US Environmental Protection Agency, 2005; US Geological Survey, 2011). 
By 2011, the use of abamectin nearly doubled to approximately 100,000 pounds per year 
due to increased penetration of the cotton market and approval as a nematicide seed 
treatment on corn throughout the US (US Environmental Protection Agency, 2011; US 
Geological Survey, 2011). 
Abamectin is highly lipophilic, adsorbs strongly to soil surfaces, and undergoes 
rapid photolysis, all of which limit the mobility and transport of abamectin from treated 
agricultural fields into surface water and groundwater (Wislocki et al., 1989). To our 
knowledge, abamectin concentrations have not been monitored within dietary (food and 
drinking water) sources of human exposure, likely because of very low foliar application 
rates (<0.025 lb active ingredient/acre) as well as minimal transport and persistence in the 




(DEEM), the US Environmental Protection Agency (EPA) recently concluded that, for 
the general US population, dietary (food and drinking water) exposures to abamectin are 
below the level of concern for acute and chronic risk using rat-based no-observable 
adverse effect levels (NOAELs) derived from acute (adult) neurotoxicity (NOAEL = 0.5 
mg/kg/day) and developmental neurotoxicity (NOAEL = 0.12 mg/kg/day) studies, 
respectively (US Environmental Protection Agency, 2013). Interestingly, although adult 
behavior was the most sensitive endpoint affected within both acute and sub-chronic 
neurotoxicity studies, pup body weight – rather than pup behavior – during post-natal 
development was the most sensitive endpoint affected within the developmental 
neurotoxicity study (US Environmental Protection Agency, 2013). Therefore, as prenatal 
development is not monitored and pups are not directly dosed within a developmental 
neurotoxicity study, these data suggest that the neurotoxic effects of abamectin in utero 
(if any) may be reversible following delivery. However, to our knowledge no studies 
have investigated the potential for abamectin-induced neurotoxicity during vertebrate 
embryonic development and whether these effects (if any) are reversible following 
elimination of abamectin exposure.  
Based on a high-content screen conducted within Chapter 2, we demonstrated that 
exposure of zebrafish embryos to abamectin from 5-25 hours post-fertilization (hpf) 
abolished spontaneous activity – an indicator of developmental neurotoxicity – in the 
absence of effects on survival and gross morphology. Therefore, as zebrafish is a well-
established model for early vertebrate neurodevelopment (Eisen et al., 1989; Westerfield 
et al., 1990), the overall objective of this study was to begin investigating the mechanism 




experiments to (1) identify developmental stages susceptible to abamectin exposure 
within the first 24 h of embryogenesis (which is roughly equivalent to the first 16 days of 
prenatal rat development); (2) determine whether abamectin-induced effects on 
spontaneous activity are reversible; and (3) identify potential molecular initiating events 
responsible for abamectin-induced hypoactivity. 
 
3.2 MATERIALS AND METHODS 
3.2.1 ANIMALS 
Adult fli1:egfp or wildtype (5D) zebrafish were raised and maintained on a 14-
hour:10-hour light:dark cycle within an Aquatic Habitats Five-Shelf Stand-Alone 
recirculating system containing photoperiod enclosures and conditioned reverse osmosis 
(RO) water (~27-28°C). Adult females and males were bred directly on-system using in-
tank breeding traps suspended within 3 L tanks. For all experiments described below, 
newly fertilized eggs were staged according to previously described methods (Kimmel et 
al., 1995). All fish were handled and treated in accordance with approved Institutional 
Animal Care and Use Committee (IACUC) protocols at the University of South Carolina 
– Columbia.   
 
3.2.2 CHEMICALS 
 Abamectin, fipronil, and endosulfan were purchased from ChemService, Inc. 
(West Chester, PA). Stock solutions of each chemical were prepared by dissolving 
chemicals in high performance liquid chromatography (HPLC)-grade dimethyl sulfoxide 




stock solutions for each working solution. All stock solutions were stored at room 
temperature within 2 mL amber glass vials containing polytetrafluoroethylene (PTFE)-
lined caps. For each individual exposure, working solutions of all treatments were freshly 
prepared by spiking stock solutions into embryo media (EM) (5 mM NaCl, 0.17 mM 
KCl, 0.33 mM CaCl2, 0.33 mM MgSO4), resulting in 0.1% DMSO within all vehicle 
control and treatment groups. 
 
3.2.3 EMBRYONIC ABAMECTIN EXPOSURES 
Newly fertilized eggs were collected immediately after spawning and placed in 
groups of approximately 100 per petri dish within a light- and temperature-controlled 
incubator until 5 hpf. Prior to each experiment, 50 mL glass beakers were thoroughly 
rinsed with DMSO and RO water. For initial screening assays, viable fli1:egfp embryos 
were exposed to vehicle (0.1% DMSO) or abamectin (0.0625-0.5 µM) in triplicate glass 
beakers (20 per replicate beaker) under static conditions at 28°C from 5 to 24 hpf. At 24 
hpf, all beakers were removed from the incubator and allowed to acclimate at 25°C 
within treatment solution for 1 hour before imaging. At 25 hpf, all embryos within each 
treatment beaker were videoed for 10 seconds under transmitted light using an Olympus 
MVX10 MacroView stereomicroscope equipped with an Olympus DP72 Digital Color 
Camera and Olympus DP2-BSW Imaging Software. Videos were analyzed manually to 
assess percent spontaneous activity within each beaker. Inactive embryos were defined as 
embryos that were immobile during the entire 10-second video (152 frames), and were 




were considered active and assigned an activity value of 1. Based on these values, percent 
spontaneous activity was then calculated for each beaker.  
To identify developmental windows susceptible to abamectin exposure within the 
first 24 h of zebrafish embryogenesis, fli1:egfp embryos were exposed to vehicle (0.1% 
DMSO) or 0.5 µM abamectin in triplicate glass beakers (20 per replicate beaker) using 
the following static exposure scenarios: (1) 5-25 hpf; (2) 10-25 hpf; and (3) 23-25 hpf. 
After beakers were removed from the incubator, embryos were acclimated at 25°C within 
treatment solution from 24-25 hpf prior to video recording under transmitted light, and 
spontaneous activity was analyzed as described above. To determine whether abamectin-
induced effects on spontaneous activity were reversible, fli1:egfp embryos were first 
placed in triplicate glass beakers (20 per replicate beaker) containing EM only at 28°C 
from 5-23 hpf. Embryos were then exposed to vehicle (0.1% DMSO) or 0.5 µM 
abamectin from 23-27 hpf at room temperature, rinsed twice, and maintained in clean 
glass beakers containing clean EM only at room temperature until 31 hpf. Although 
previous studies have concluded that spontaneous activity occurs between approximately 
19 and 29 hpf (Saint-Amant and Drapeau, 1998), we have found that, at 28°C, activity 
within vehicle control embryos continues beyond 31 hpf, enabling the measurement of 
activity for a 4-hour recovery period. A “baseline” video was recorded for each beaker 
before treatment solutions were added, and subsequent videos were recorded every 15 
minutes under transmitted light. Although we did not use a FITC filter cube for imaging, 
we used fli1:egfp embryos to be consistent with our study in Chapter 2 and, while not 




of spontaneous activity. Percent spontaneous activity was then determined for each 
beaker at each time point as described above. 
 
3.2.4 IN SITU ASSESSMENT OF PRIMARY MOTONEURON MORPHOLOGY WITHIN 25-HPF 
ZEBRAFISH EMBRYOS 
 Wildtype (5D) embryos were exposed in triplicate glass beakers to either vehicle 
(0.1% DMSO) or 0.5 µM abamectin from 5-25 hpf at 28°C. Live embryos were then 
dechorionated by incubating embryos in 0.5 mg/mL pronase for 20 minutes on a shaker 
at 100 rpm. Embryos were then washed in RO water and fixed overnight in 4% 
paraformaldehyde. Fixed embryos were permeabilized by incubating in cold acetone at    
-20°C for 15 minutes, and then rinsed four times in phosphate-buffered saline 
(PBS)/0.1% Tween-20 (PBST) for 5 minutes per wash. Permeabilized embryos were 
incubated in fresh blocking buffer (PBST/2% sheep serum/2 mg/mL bovine serum 
albumin) for 4 hours at room temperature with gentle agitation, and then incubated 
overnight at 4°C with gentle agitation in blocking buffer containing a 1:20 dilution of 
znp-1 IgG2a supernatant (DSHB, University of Iowa). znp-1 IgG2a is a zebrafish-specific 
antibody that recognizes cell bodies and axons of primary motoneurons in 25-hpf 
zebrafish (Pike et al., 1992; Trevarrow et al., 1990). Following primary antibody 
incubation, embryos were washed five times with gentle agitation in PBST at room 
temperature for 15 minutes each. Embryos were incubated overnight at 4°C with gentle 
agitation in blocking buffer containing a 1:500 dilution of Alexa Fluor 488 (AF488)-
conjugated goat anti-mouse IgG2a (Invitrogen) to visualize znp-1 localization in situ. 




agitation in PBST at room temperature for 15 minutes each, and then stored in PBS at 
4°C until imaging. Labeled embryos were imaged at 10X magnification using a FITC 
filter cube and Olympus BX51 Research System Microscope equipped with an Olympus 
DP72 Digital Color Camera and Olympus DP2-BSW Imaging Software. 
 
3.2.5 EMBRYONIC EXPOSURES WITH GABA RECEPTOR ANTAGONISTS 
We used fipronil and endosulfan – two insecticides that antagonize the GABA 
receptor – to test whether abamectin-induced hypoactivity was mediated through the 
GABA receptor. To identify the maximum tolerated concentration that did not adversely 
impact spontaneous activity, range-finding exposures for fipronil (3.125-25 µM) and 
endosulfan (0.625-5 µM) alone were first conducted under static exposure conditions in 
50 mL beakers as described above. Based on these range-finding exposures, the final no-
effect concentration used for these experiments was 12.5 µM and 1.25 µM for fipronil 
and endosulfan, respectively. First, three replicate beakers of fli1:egfp embryos (20 per 
replicate beaker) were pretreated with vehicle (0.1% DMSO), 12.5 µM fipronil, or 1.25 
µM endosulfan from 5-23 hpf at 28°C. Embryos were then washed twice with clean EM 
and exposed to vehicle (0.1% DMSO) or 0.5 µM abamectin in clean beakers from 23-25 
hpf. After a 1 hour acclimation from 24-25 hpf, videos were recorded and spontaneous 
activity was analyzed as described above.   
 
3.2.6 TOTAL RNA ISOLATION AND REAL-TIME PCR 
Four replicate pools of 5-, 10-, and 23-hpf zebrafish embryos (100 individuals per 




80°C. Following homogenization of embryos using a PowerGen Homogenizer (Fisher 
Scientific), an SV Total RNA Isolation System (Promega) was used to extract total RNA 
from pooled embryos. Prior to sample elution, total RNA samples were on-column-
digested with DNase-I to remove any DNA contamination. Total RNA concentrations 
and 260/280 ratios were determined using a Nano Drop ND-2000 spectrophotometer and 
samples were stored at -80°C.  
 Per manufacturer’s instructions, first-strand cDNAs were generated from total 
RNA samples using oligo (dT)15 primers and AMV Reverse Transcriptase (Promega); all 
cDNA samples were stored at -20°C until use. gabra1, gabrb2, gabrg2, and 18s rRNA 
cDNAs were amplified using the following primers: gabra1, forward primer 5’-
GTCTGTTACGCCTTTGTCTTCT-3’, reverse primer 5’-GCGGTGTAGG 
TGTTGTTCTT -3’; gabrb2, forward primer 5’-GTGGCGGTAGGGATGAATATAG-3’, 
reverse primer 5’-ACGCGGTTATCCAAGGTTAG-3’; gabrg2, forward primer 5’-
TACGGAACGCTACACTACTTTG-3’, reverse primer 5’-CCAGACATTCGTAGCC 
GTATT -3’; and 18s rRNA, forward primer 5’-TCGCTAGTTGGCATCGTTTATG-3’, 
reverse primer 5‘CGGAGGTTCGAAGACGATCA-3’. As 18s rRNA is stably expressed 
throughout zebrafish embryogenesis (McCurley and Callard, 2008), this gene was 
selected as an internal control for each developmental stage. Per manufacturer’s 
instructions, approximately 75 ng of cDNA for each target was PCR amplified using 
GoTaq qPCR Master Mix (Promega) and an Applied Biosystems 7900HT Fast Real-
Time PCR System. Real-time PCR reaction conditions were 2 minutes at 95°C followed 
by 45 cycles of 95°C for 30 seconds, 50°C for 30 seconds, and 72°C for 15 seconds. 




comparative cycle threshold (Ct) method as previously described (Jayasinghe and Volz, 
2012). 
 
3.2.7 PHYLOGENETIC ANALYSIS 
Gene and protein databases available within the National Center for 
Biotechnology Information (NCBI) were searched to find protein sequences for all 
zebrafish ionotropic GABA receptor (also known as GABAAR) subunits. If protein 
sequences submitted to NCBI were not available, we relied on protein sequences 
predicted from the most current assembly of the zebrafish genome Zv9 
(http://www.ncbi.nlm.nih.gov/genome?term=danio%20rerio). Due to minor differences 
in NCBI’s nomenclature for GABA receptor α4 subunit, the Basic Local Alignment 
Search Tool (BLAST) was used to find the zebrafish homolog for the human GABA 
receptor α4 subunit. For each zebrafish GABA receptor subunit, BLAST Link (BLink) 
was used to obtain the most similar protein sequence within rat (Rattus norvegicus), 
mouse (Mus musculus), and human (Homo sapiens). Multiple alignment of all protein 
sequences (61 total) was conducted using EMBL-EBI’s Clustal Omega 
(http://www.ebi.ac.uk/Tools/msa/clustalo/), and alignment results were imported into 
EMBL-EBI’s ClustalW2 Phylogeny to generate a phylogenetic tree 
(http://www.ebi.ac.uk/Tools/phylogeny/clustalw2_phylogeny/). 
 
3.2.8 STATISTICAL ANALYSES 
All statistical procedures were performed using SPSS Statistics 21.0 (Chicago, 




analysis of variance (ANOVA) (α = 0.05) was used, as these data did not meet the equal 
variance assumption for non-GLM ANOVAs. For analysis of real-time PCR data, a GLM 
ANOVA (α = 0.05) was used to compare Ct values for gabra1 across all three 
developmental stages. Pair-wise Tukey-based multiple comparisons of least square means 
were performed to identify significant stage- or treatment-related effects. 
 
3.3 RESULTS 
3.3.1 ABAMECTIN ABOLISHES SPONTANEOUS ACTIVITY WITHIN EARLY ZEBRAFISH EMBRYOS  
Using a 384-well-based high-content screening assay, we demonstrated in 
Chapter 2 that exposure of developing zebrafish embryos to ≥3.125 µM abamectin – an 
avermectin insecticide – from 5-25 hpf abolished spontaneous activity in the absence of 
effects on survival and gross morphology. Due to shifting our focus away from screening 
as well as logistical challenges associated with aspirating treatment solution from 384-
well plates, we completed all follow-up experiments within glass beakers. For this study, 
we first exposed embryos to abamectin within 50 mL glass beakers to identify the 
nominal concentration that completely eliminated spontaneous activity, as we expected 
this concentration to be less than the concentration within glass-bottom 384-well plates 
due to greater sorption of abamectin to plastic well walls. Similar to 384-well plates, 
static exposure of 5-hpf zebrafish embryos to abamectin in glass beakers resulted in a 
concentration-dependent decrease in percent spontaneous activity at 25 hpf in the absence 
of effects on survival (≥85% average survival across all concentrations tested) (Figure 
3.1). However, complete elimination of spontaneous activity was observed at 0.5 µM 




required to eliminate spontaneous activity within 384-well plates. Therefore, as exposure 
to 0.5 µM abamectin did not result in gross abnormalities, we relied on this exposure 
concentration for all subsequent experiments. 
 
3.3.2 ABAMECTIN DOES NOT AFFECT NEURITE OUTGROWTH OF SPINAL MOTONEURONS 
To determine whether exposure to abamectin from 5-25 hpf affected neurite 
outgrowth within zebrafish embryos, we used whole-mount immunohistochemistry to 
label the axons of primary motoneurons in situ. Similar to fli1:egfp embryos, exposure of 
wildtype (5D) embryos to 0.5 µM abamectin eliminated spontaneous activity. Although 
survival was ≥90% and all vehicle- and abamectin-exposed embryos developed normally, 
abamectin exposure did not appear to impact neurite outgrowth of primary motoneurons 
compared to vehicle-exposed embryos (Figure 3.2), suggesting that abamectin-induced 
elimination of spontaneous activity was not associated with effects on primary 
motoneuron development. 
 
3.3.3 ABAMECTIN INDUCES RAPID EFFECTS ON SPONTANEOUS ACTIVITY 
To identify developmental stages susceptible to abamectin-induced hypoactivity 
within the first 25 hours of zebrafish embryogenesis, we initiated exposure of embryos to 
vehicle or 0.5 µM abamectin at 5, 10, and 23 hpf and then evaluated spontaneous activity 
at 25 hpf. Average survival across all exposure groups was ≥95% (Figure 3.3A), and 
average spontaneous activity within vehicle-exposed embryos was 83% (Figure 3.3B). 
Surprisingly, similar to exposures initiated at 5 hpf, developing zebrafish embryos were 




10 and 23 hpf (Figure 3.3B). Given that a 2-hour exposure resulted in nearly identical 
effects as a 20-hour exposure, these data suggest that, rather than impacting 
neurodevelopment, abamectin induced rapid neurophysiological effects within early 
zebrafish embryos. 
 
3.3.4 ABAMECTIN-INDUCED HYPOACTIVITY IS REVERSIBLE FOLLOWING TRANSFER TO 
CLEAN EMBRYO MEDIA 
As the effects of abamectin on spontaneous activity were rapid, we then 
determined whether abamectin-induced effects on spontaneous activity were reversible. 
Embryos were exposed to vehicle or 0.5 µM abamectin from 23-27 hpf, and then 
transferred to clean EM until 31 hpf. Baseline (pretreatment) spontaneous activity for 
embryos within beakers labeled for vehicle or abamectin exposure was 86.7 and 87.5%, 
respectively (Figure 3.4). During the 4-hour exposure period, spontaneous activity within 
vehicle-exposed embryos remained relatively stable and ranged from 82 to 97% (Figure 
3.4). Although activity within vehicle-exposed embryos started to decline toward the end 
of the 4-h recovery period, there were no significant differences in spontaneous activity at 
all time points compared to within-vehicle baseline activity. On the contrary, addition of 
abamectin resulted in a rapid decline in spontaneous activity from 23-27 hpf (Figure 3.4). 
Compared to within-treatment baseline activity, a significant decrease in percent 
spontaneous activity was observed at 24.75 hpf – only 1.75 hours after initiation of 
abamectin exposure – and spontaneous activity continued to decline, reaching as low as 
7.5% by the end of the 4-hour exposure period (Figure 3.4). However, transfer of 




activity from 27-31 hpf, with complete recovery observed by 30.25 hpf – approximately 
3.25 h after immersion within clean EM. 
 
3.3.5 ABAMECTIN-INDUCED HYPOACTIVITY IS BLOCKED BY PRETREATMENT WITH GABA 
ANTAGONISTS 
To test the hypothesis that abamectin-induced hypoactivity within zebrafish 
embryos was mediated through reversible activation of GABA-gated chloride channels, 
we pretreated zebrafish embryos to vehicle or non-toxic concentrations of fipronil or 
endosulfan – two insecticides that antagonize the GABA receptor – from 5-23 hpf, and 
then exposed embryos to vehicle or abamectin from 23-25 hpf. Based on initial range-
finding exposures with fipronil and endosulfan, average embryo survival across all 
exposure groups was ≥98% (Figure 3.5A and B), and a significant decrease in percent 
spontaneous activity was observed at the highest concentration tested (Figure 3.5C and 
D). Therefore, for pretreatment experiments with abamectin, we selected 12.5 µM 
fipronil and 1.25 µM endosulfan as the maximum tolerated concentrations based on the 
absence of effects on spontaneous activity (Figure 3.5C and D). 
In pretreatment experiments with either fipronil or endosulfan, average survival 
within all exposure groups was ≥90% (Figure 3.6A and B). Spontaneous activity within 
vehicle controls was at least 74% and, in both cases, hypoactivity was observed within 
abamectin-exposed embryos pretreated with vehicle (Figure 3.6C and D). However, 
spontaneous activity within abamectin-exposed embryos pretreated with 12.5 µM fipronil 
(Figure 3.6C) or 1.25 µM endosulfan (Figure 3.6D) ranged from 74 to 87% and was not 




hypoactivity was blocked by pretreatment with non-toxic concentrations of two GABA 
receptor antagonists, suggesting that abamectin-induced hypoactivity may be mediated 
through the GABA receptor. 
 
3.3.6 GABRA1 AND GABRB2 ARE EXPRESSED DURING EARLY STAGES OF EMBRYONIC 
DEVELOPMENT  
 As the α1, β2, and γ2 subunits are the most prevalent ionotropic GABA receptor 
subunits within the rat brain (Dawson et al., 2000; Johnston, 1996; McKernan and 
Whiting, 1996; Whiting, 2003), we measured the relative levels of gabra1, gabrb2, and 
gabrg2 transcripts at 5, 10, and 23 hpf using real-time PCR to determine whether these 
subunits were present during early development. Since gabrg2 transcripts were non-
detectable at all three stages (data not shown), we focused our analysis on gabra1 and 
gabrb2, both of which were detected at 5, 10, and 23 hpf. Relative to gabrb2, gabra1 
transcripts were ~70-fold lower at 5 hpf but ~75- and ~17-fold higher at 10 and 23 hpf, 
respectively (Figure 3.7). In addition, gabra1 transcript levels were significantly different 
from one another across all three developmental stages (Figure 3.7). 
 
3.3.7 IONOTROPIC GABA RECEPTOR SUBUNITS WITHIN ZEBRAFISH AND MAMMALS ARE 
HOMOLOGOUS 
To determine whether protein sequences of zebrafish and mammalian ionotropic 
GABA receptor subunits were similar, we constructed a phylogenetic tree to compare 
GABA receptor subunits across four species: zebrafish, rat, mouse, and human. As 




receptor α6 and α4 subunits, the majority of GABA receptor subunits sharing the same 
letter (i.e., γ, ρ, and β) clustered into distinct clades and, within each clade, rat, mouse, 
and human subunits were more similar to each other relative to zebrafish (Figure 3.8). 
Therefore, these data indicate that zebrafish and mammalian ionotropic GABA receptor 
subunits are homologous, similarities that are likely due to highly conserved and 
functionally important sequence domains (e.g., ligand-binding domain) within vertebrate 
ionotropic GABA receptor subunits. 
 
3.4 DISCUSSION 
Using zebrafish as a model, the objective of this study was to begin investigating 
the mechanism of abamectin-induced hypoactivity during embryonic development and 
explore whether this effect was reversible following cessation of exposure. After 
confirming that static exposure of embryos to 0.5 µM abamectin from 5-25 hpf in glass 
beakers eliminated spontaneous activity, we demonstrated that (1) abamectin did not 
affect neurite outgrowth from spinal motoneurons; (2) compared with exposure from 5-
25 hpf, developing embryos were equally susceptible to abamectin-induced hypoactivity 
when exposures were initiated at 10 and 23 hpf; and (3) abamectin-induced hypoactivity 
was reversible after immersion of exposed embryos in clean water. Using fipronil and 
endosulfan (insecticides that antagonize the GABA receptor) as pharmacologic tools, we 
found that pretreatment of embryos with non-toxic concentrations of either antagonist 
from 5-23 hpf, followed by exposure to abamectin from 23-25 hpf, resulted in 
spontaneous activity levels similar to embryos exposed to vehicle alone. Finally, using 




receptor α1 and β2 subunits in zebrafish at 5, 10, and 23 hpf, and demonstrated that 
zebrafish ionotropic GABA receptor subunits are homologous to mammalian ionotropic 
GABA receptor subunits. 
Due to the difficulty in assessing behavioral endpoints in utero, little is known 
about the potential effects of abamectin exposure during vertebrate embryonic 
development. Our results showed that, within abamectin-exposed embryos, elimination of 
spontaneous activity occurred in the absence of effects on survival and neurite outgrowth 
of spinal motoneurons. However, this effect on locomotion was rapid, as spontaneous 
activity within zebrafish embryos decreased to nearly 7% after just 2 h of abamectin 
exposure (23-25 hpf), suggesting that abamectin induces rapid, functional effects on the 
nervous system rather than affecting motoneuron growth. Given that abamectin is 
moderately hydrophobic (low Kow = 4.4), rapid abamectin transport across the chorion 
into the embryo likely accounted for the rapid decrease in spontaneous activity observed 
(US Environmental Protection Agency, 2010). Similarly, in a 14-d acute neurotoxicity 
study within adult rats, the most sensitive endpoints affected after exposure to the highest 
abamectin concentration (6.0 mg/kg/day) by oral gavage included tiptoe gait, reduced 
splay reflex, and, most relevant to this study, decreased motor activity (US 
Environmental Protection Agency, 2013). Despite rapid abamectin-induced hypoactivity 
within 4 h of exposure, embryos quickly recovered 3.5 h following transfer to clean 
water, suggesting that abamectin reversibly binds to ligand-gated chloride channels and 
inhibits neurotransmission. Although spontaneous activity within vehicle-exposed 




narrow time window for this behavior during normal embryonic development (Saint-
Amant and Drapeau, 2000).  
Interestingly, the sedative, anticonvulsant effects of abamectin observed in 
zebrafish and rats are similar to effects produced in mice and humans following exposure 
to benzodiazepines and other compounds that interact with the GABA receptor complex 
(Dawson et al., 2000; Zanette et al., 2013). These types of compounds – including 
barbiturates, benzodiazepines and ethanol – fall into a larger class of drugs known as 
sedative-hypnotics, and are used to reduce tension and anxiety, relax muscles, and/or 
induce sleep (Boles and Miotto, 2003). Therefore, spontaneous activity represents an 
integrative behavioral readout that, combined with transparent, ex utero development of 
zebrafish embryos, allows for control of exposure and recovery windows and, as such, 
can be used to identify compounds with an abamectin-like mechanism of action.  
Abamectin is thought to induce neurotoxicity in invertebrates and vertebrates by 
activation of ligand-gated chloride channels, interfering with signal transmission between 
nerve cells (Bloomquist, 1996). In vertebrates, although both GABA and glycine 
receptors are selective for chloride, previous findings demonstrate that abamectin-
induced toxicity occurs primarily through activation of GABA-gated chloride channels 
(Coccini et al., 1993; Dawson et al., 2000). We demonstrated that pretreatment of 
embryos with non-toxic concentrations of fipronil and endosulfan – two insecticides that 
antagonize the GABA receptor – blocked abamectin-induced hypoactivity. Although 
higher concentrations of both antagonists resulted in decreased spontaneous activity, this 
is consistent with the paralyzing effects of GABA receptor antagonists at toxic 




neurons (Connelly, 2001). Though fipronil has been shown to inhibit glycine receptor 
isoforms (Islam and Lynch, 2012), GABA receptors have been implicated as the primary 
target for both fipronil and endosulfan (Cole et al., 1993; Eldefrawi and Eldefrawi, 1987). 
In addition, we recognize that these insecticides may have the potential to bind other 
receptors within zebrafish embryos; however, initial attempts to pretreat embryos with 
strychnine – a rodenticide that antagonizes the glycine receptor – failed to block the 
hypoactive effects of abamectin (Figure B.3). The ability of fipronil (a phenylpyrazole 
insecticide) and endosulfan (a cyclodiene insecticide) – two hydrophobic compounds 
with distinct chemical structures – to prevent abamectin-induced hypoactivity suggests 
that abamectin-induced inhibition of neurotransmission within 25-hpf zebrafish embryos 
may be mediated through the GABA receptor.  
At the time spontaneous tail contractions commence, three primary motoneurons 
and seven interneurons are present within the zebrafish spinal cord (Brustein, 2003). As 
the neurotransmitter GABA is not localized to primary motoneurons in 26-hpf zebrafish 
(Tallafuss and Eisen, 2008), these findings relative to our data suggests that abamectin 
may act within the central nervous system, blocking signal transmission from 
interneurons to excitatory motoneurons (Campbell et al., 1983). While abamectin may 
inhibit neurotransmission by direct binding to the GABA receptor or increasing 
endogenous GABA concentrations (Novelli et al., 2012), there is evidence that the 
GABA receptor β subunit is a key subunit for avermectin activity (Arena et al., 1993) and 
that abamectin potentiates β1- and β2-containing GABA receptors (Dawson et al., 2000). 
Our quantitative PCR data demonstrate that β2 and α1 GABA receptor subunits are 




present at 23 hpf, the time point when addition of abamectin eliminates spontaneous 
activity. Although we have not amplified additional GABA receptor subunits, some of 
these subunits are likely present at 23 hpf. Although the presence of these subunits does 
not confirm whether abamectin eliminates activity by interacting with the GABA 
receptor, these data do indicate the potential for this interaction to occur. Moreover, our 
phylogenetic analyses show that zebrafish and mammalian ionotropic GABA receptor 
subunits are homologous, demonstrating that if abamectin is interacting with the GABA 
receptor in zebrafish, this finding may have relevance to rodent models and humans.  
In summary, this study resulted in three major findings: 1) abamectin-induced 
hypoactivity within zebrafish embryos occurs within 2 h of exposure, an effect that is 
reversed following transfer of abamectin-exposed embryos to clean water; 2) abamectin-
induced hypoactivity is blocked by pretreatment with non-toxic concentrations of fipronil 
and endosulfan, two insecticides that antagonize the GABA receptor; and 3) GABA 
receptor subunits present within the first 24 h of zebrafish embryogenesis are 
homologous to mammalian GABA receptor subunits. While our data suggests that 
abamectin-induced hypoactivity during embryonic development may not result in long-
term locomotive effects, there may be a need to evaluate the potential long-term effects 
of early abamectin exposure on cognition at later stages of development. Moreover, our 
study supports the conclusion that spontaneous activity represents an integrative 
behavioral readout that has the potential to detect GABA receptor agonists – and likely 
other neuroactive chemicals – within a physiologically relevant, intact organism. 




useful as a model for screening and prioritizing chemicals for developmental 








Figure 3.1: Abamectin exposure from 5-25 hpf results in a concentration-dependent 
decrease in spontaneous activity in the absence of effects on survival, with complete 
elimination of spontaneous activity observed at 0.5 µM abamectin. (A) Survival (mean ± 
SD) and (B) spontaneous activity (mean ± SD) following exposure to vehicle (0.1% 
DMSO) or 0.0625-0.5 µM abamectin. Numbers above each bar denote mean percent 
spontaneous activity. Asterisk (*) denotes significant difference in percent spontaneous 
activity from vehicle control (p<0.05). N = three replicate beakers per treatment and 20 







Figure 3.2: Abamectin does not affect gross primary motoneuron morphology of 25-hpf 
zebrafish embryos. Fixed wildtype (5D) embryos exposed to vehicle (0.1% DMSO) or 
abamectin (0.5 µM) from 5-25 hpf were incubated in znp-1 antibody overnight at 4°C 






Figure 3.3: Zebrafish embryos are susceptible to abamectin-induced hypoactivity 
following initiation of exposure at 5, 10 or 23 hpf. (A) Survival (mean ± SD) and (B) 
spontaneous activity (mean ± SD) following exposure to vehicle (0.1% DMSO) from 5-
25 hpf or 0.5 µM abamectin from 5-25 hpf, 10-25 hpf, or 23-25 hpf. Numbers above each 
bar denote mean percent spontaneous activity. Asterisk (*) denotes significant difference 
in percent spontaneous activity from vehicle control (p<0.05). N = three replicate beakers 





Figure 3.4: Immersion of abamectin-exposed embryos in clean EM results in complete recovery of spontaneous activity relative to 
vehicle-exposed embryos. Spontaneous activity (mean ± SD) during exposure to vehicle (0.1% DMSO) or 0.5 µM abamectin from 23-
27 hpf, with subsequent recovery in clean EM from 27-31 hpf. Asterisk (*) denotes significant difference in percent spontaneous 
activity compared to within-treatment baseline (p<0.05). N = three replicate beakers per treatment and 20 initial embryos per replicate 
beaker. Baseline reading was measured immediately prior to adding treatment solution. The dotted line indicates when embryos were 





Figure 3.5: Fipronil or endosulfan exposure from 5-25 hpf results in a decrease in 
spontaneous activity at the highest concentrations tested in the absence of effects on 
survival. (A, B) Survival (mean ± SD) or (C, D) spontaneous activity (mean ± SD) at 25 
hpf following exposure to vehicle (0.1% DMSO), 3.125-25 µM fipronil or 0.625-5 µM 
endosulfan from 5-25 hpf. Numbers above each bar denote mean percent spontaneous 
activity. Asterisk (*) denotes significant difference in percent spontaneous activity from 
vehicle control (p<0.05). N = three replicate beakers per treatment and 20 initial embryos 













Figure 3.6: Abamectin-induced hypoactivity is blocked by pretreatment of embryos with 
non-toxic concentrations of fipronil or endosulfan. (A, B) Survival (mean ± SD) and (B, 
D) spontaneous activity (mean ± SD) at 25 hpf following exposure to vehicle (0.1% 
DMSO) or 0.5 µM abamectin (23-25 hpf) with or without fipronil or endosulfan 
pretreatment (5-23 hpf). Plus (+) or minus (-) signs indicate the presence or absence, 
respectively, of a chemical for each treatment. Numbers above each bar denote mean 
percent spontaneous activity. Asterisk (*) denotes significant difference in percent 
spontaneous activity from vehicle control (p<0.05). N = three replicate beakers per 






Figure 3.7: gabra1 and gabrb2 transcripts are present at 5, 10 and 23 hpf within normal 
developing zebrafish embryos. Fold change data are mean ± SD relative to gabrb2 for 
each developmental stage. Developmental stages that do not share the same letter are 
significantly different (p < 0.05) from each other. N = three (10 hpf) or four (5 and 23 







Figure 3.8: Phylogenetic analysis demonstrates that zebrafish ionotropic GABA receptor 
(GABAAR) subunits are homologous to rodent and human ionotropic GABA receptor 
subunits. Multiple alignment of all protein sequences (61 total) was conducted using 
EMBL-EBI’s Clustal Omega, and alignment results were imported into EMBL-EBI’s 
ClustalW2 Phylogeny to generate a phylogenetic tree. 
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CHAPTER 4
CONCLUSIONS AND FUTURE RESEARCH 
Within the United States, approximately one out of six children has a 
developmental disability, most of which affect the nervous system  (Grandjean and 
Landrigan, 2006). Treatment of neurodevelopmental disorders is difficult, and the 
resulting disabilities may often be permanent and result in high damage and costs to 
family and society. Moreover, in the last few decades, the observed increase in 
neurodevelopmental disorders in children is thought to be partly due to increased 
environmental exposure to potential neurotoxicants. In fact, roughly 3% of 
neurodevelopmental disabilities may be due to exposure to environmental toxicants, 
while 25% may arise due to gene-environment interactions (Giordano and Costa, 2012). 
Although social factors are also believed to contribute to this increasing trend, there is 
mounting evidence that demonstrates associations between environmental chemicals and 
neurodevelopmental disorders. Consequently, DNT has now become an issue of growing 
concern around the world, and the efforts of scientists and regulators are focused on 
understanding the potential hazards of these chemical agents to help fill existing DNT 
data gaps (National Research Council, 2000). As a result, there is general agreement 
regarding the need to develop alternative test methods that are rapid and can be validated 
and used across multiple laboratories. While these methods must not only help generate 
reliable data that are predictive and effective, they should also accommodate screening 
large numbers of chemicals. Therefore, developing a battery of HCS/HTS assays for 
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DNT that emphasizes the use of alternative animal models and can be used within a 
regulatory context is an important priority.  
The first study (Chapter 2) demonstrated that HCS assays that rely on 
neurobehavioral endpoints in zebrafish embryos can be used to 1) screen and prioritize 
potential developmental neurotoxicants for further testing in other animal models and 2) 
provide a foundation for developing hypothesis-driven mechanistic studies in zebrafish 
embryos. For example, using the HCS assay described in Chapter 2, we identified two 
chemicals - abamectin and emamectin benzoate – that significantly decreased 
spontaneous activity in the absence of effects on survival and total body area. Although 
spontaneous activity in zebrafish occurs a very early developmental stage (which cannot 
be easily assessed in utero in mammals) and may not have direct phenotypic relevance to 
rodent models or humans, these results can help predict potential neurotoxic effects of 
chemicals that may have similar molecular targets in zebrafish and humans. In fact, 
similar behavioral assays in zebrafish have been developed as ways to promote drug 
discovery and even screen chemicals for neurotoxicity (Kokel et al., 2010).  
Even though the HCS assay described in Chapter 2 was successful in identifying 
potential developmental neurotoxicants during early zebrafish embryogenesis, the assay 
had a few limitations. First, because spontaneous behavior is naturally variable and 
occurs within a narrow time window during normal embryonic development, we were 
only able to image 192 embryos (one well at a time) over an 80-minute time period using 
a 2x objective. However, future research can begin to optimize the assay using a 1x 
objective, which allows imaging of four wells together. Therefore, 384 embryos could be 
imaged in just half the time (40 minutes) required to image 192 embryos using a 2x 
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objective. This would also increase the sample size from 16 to 32 embryos per treatment 
(one to two columns), allowing for multiple plates to be imaged per day. Ideally, this 
would help control for the natural variation in spontaneous activity while also increasing 
throughput. 
Furthermore, the two positive hits identified in our screen had similar modes-of-
action, suggesting that this HCS assay may be biased towards identifying chemicals with 
only specific neurotoxic modes-of-action, particularly at this early embryonic stage of 
development. In addition, we only identified chemicals that resulted in hypo- rather than 
hyper-activity. However, this initial screen comprised only a small subset of chemicals, 
and the observed hit rate (1 out of 15, or 6.7%) is consistent with the hit rate of another 
zebrafish behavioral screening assay (Kokel et al., 2010). In the future, increasing the 
throughput of this assay would allow a larger battery of chemicals to be screened and 
help determine whether this assay could potentially be used to group chemicals that share 
common mechanisms of action and chemical structures (Kokel et al., 2010). Nonetheless, 
these results support the use of this HCS assay to help identify potential developmental 
neurotoxicants within a regulatory context. 
The identification of abamectin as a potential developmental neurotoxicant led us 
to develop hypothesis-driven studies to begin investigating the mechanism of abamectin-
induced hypoactivity. The second study (Chapter 3) demonstrated that 1) abamectin did 
not affect outgrowth of spinal motoneurons, 2) abamectin-induced hypoactivity was rapid 
and reversible, 3) abamectin-induced hypoactivity was blocked by pretreatment with two 
GABA receptor antagonists, and 4) GABA receptor subunits within zebrafish and 
mammals are homologous, suggesting that this has potential relevance to mammalian 
 75 
systems. Based on the observed behavioral effect and known effects of GABA, we then 
hypothesized that abamectin-induced hypoactivity occurs due to an influx of chloride 
ions into interneurons, resulting in decreased membrane potential. However, initial 
attempts within zebrafish embryos to assess voltage changes using the FLIPR assay were 
unsuccessful. Future studies should rely on whole-cell patch clamp recording techniques 
to assess voltage changes of zebrafish spinal cord neurons in vehicle and abamectin-
exposed embryos with or without addition of fipronil or endosulfan (GABA antagonists). 
The addition of exogenous GABA should be used as a positive control in these studies. In 
fact, the patch clamp technique has been used to successfully evaluate voltage changes of 
interneurons, motoneurons, and sensory neurons in vivo within the spinal cord of 18-26 
hpf zebrafish embryos (Saint-Amant and Drapeau, 2003).  
In addition, it is still unclear whether abamectin-induced hypoactivity occurs by 
direct chemical binding to the GABA receptor (as an agonist or antagonist), or by 
stimulating production of GABA, which is then released into the presynaptic inhibitory 
terminals (Novelli et al., 2012). Due to the rapid recovery of this behavior, we 
hypothesize that abamectin potentiates the effect of GABA by binding to a site on GABA 
receptors different from the active site. This would produce an effect similar to the 
sedative, anxiolytic behavior observed with diazepam (Valium), a benzodiazepine drug 
(Christian et al., 2013). Therefore, future studies should rely on 1) high-performance 
liquid chromatography (HPLC) to quantify the amount of GABA neurotransmitter after 
exposure to abamectin, 2) qPCR to determine whether genes involved in synthesizing or 
transporting GABA are altered, and 3) ligand-binding assays. Together, these 
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experiments would provide more detailed information about the mechanism of 
abamectin-induced hypoactivity. 
 Additional follow-up studies could also be conducted to determine whether 
abamectin exposure during early embryonic development has effects on other locomotive 
behaviors, such as touch-response or swimming, potential long-term effects on cognition, 
such as learning and memory, or multigenerational effects. Though our results suggest 
that abamectin-induced hypoactivity is likely reversible, some industrial chemicals have 
been found to exhibit “silent neurotoxicity” – a term that indicates the presence of 
subclinical effects which are not monitored within health statistics. One example of this is 
lead, a known developmental neurotoxicant, which is thought to affect IQ scores in the 
absence of visible health effects, resulting in high economic costs to society (Grandjean 
and Landrigan, 2006). Therefore, future work should aim to understand the effect of early 
abamectin exposure on behavior and cognition at later stages (juvenile or adult) in order 
to assess whether in utero exposure during early development has potential long-term 
effects on the nervous system. 
Finally, although zebrafish is a valuable in vivo model for understanding how 
chemicals act within an intact organism, future in vitro studies using human cell lines 
would complement these data, enhancing human relevance. In fact, there are numerous 
human cell lines already available that are specific to the nervous system. For example, 
human umbilical cord blood stem cells have been used to generate neural stem cell lines, 
and human neural progenitor cells have been grown as neurospheres, allowing both the 
embryonic and fetal periods of neurodevelopment to be explored in vitro (Bal-Price et al., 
2012; Smirnova et al., 2014). Neurospheres from different species can also be used to 
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compare various toxicity endpoints across species (Smirnova et al., 2014). Recently, 
human embryonic stem cells were even differentiated in vitro for DNT testing using 
methylmercury (Bal-Price et al., 2012). Within a tiered testing strategy, the use of in vivo 
data from zebrafish HCS/HTS assays or rodent models in combination with in vitro data 
from human cell lines will help improve species extrapolation to humans. Moreover, 
many imaging systems, including our ImageXpress Micro High-Content Imaging 
System, already comprise established protocols to assess endpoints such as cell viability 
and neurite outgrowth.  
Overall, the work presented in this dissertation uses zebrafish as an alternative 
animal model to help identify and prioritize chemicals for high-cost, low-throughput 
DNT assays in rodent models, while also exploring the potential mechanism of action of 
abamectin – a chemical identified as a positive hit in the HCS assay - within early 
zebrafish embryos. Ultimately, a combination of assays with different endpoints will be 
needed to effectively predict in vivo DNT, as assays in cell lines and small animal models 
are not sufficient predictors of risk to humans on their own. The development of 
HCS/HTS assays to screen and prioritize chemicals and the use of zebrafish for follow-up 
mechanistic studies will reduce animal use as well as provide a means of defining hazard 
for the thousands of chemicals in commerce with unknown toxicity data, helping fill the 
current DNT data gaps. These data can then be used to help guide regulatory decisions 
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HCS ASSAY OPTIMIZATION AND SUPPLEMENTAL DATA FOR SCREENING 
Table A.1: Chemical name, chemical formula, CAS registry number, vendor, and purity 
of all chemicals screened. 
 
Chemical Name Chemical Formula CAS# Vendor 
Purity 
(%) 
Nicotine C10H14N2 54-11-5 ChemService Inc. 99.2 
Paraoxon C10H14NO6P 311-45-5 ChemService Inc. 97.5 
Rotenone C23H22O6 83-79-4 ChemService Inc. 97.8 
Thiram C6H12N2S4 137-26-8 ChemService Inc. 99.5 
Tefluthrin C17H14ClF7O2 79538-32-2 N/A N/A 
Butafenacil C20H18ClF3N2O6 134605-64-4 Sigma Aldrich 99.3 
Pyridaben C19H25ClN2OS 96489-71-3 ChemService Inc. 99.5 
Flumetralin C16H12ClF4N3O4 62924-70-3 ChemService Inc. 99.5 
Fluthiacet-methyl C15H15ClFN3O3S2 117337-19-6 Sigma Aldrich 99.9 
Abamectin C48H72O14 (B1a) C47H70O14 (B1b) 
71751-41-2 ChemService Inc. 97.0 
Fentin C18H16OSn 76-87-9 ChemService Inc. 98.7 
Propargite C19H26O4S 2312-35-8 ChemService Inc. 99.0 
Milbemectin C31H44O7 51596-10-2 N/A N/A 
Pyraclostrobin C19H18ClN3O4 175013-18-0 ChemService Inc. 99.5 
(Z,E)-
Fenpyroximate C24H27N3O4 134098-61-6 ChemService Inc. 99.5 
Tribufos C12H27OPS3 78-48-8 ChemService Inc. 98.1 
Famoxadone C22H18N2O4 131807-57-3 ChemService Inc. 98.5 
Fluoxastrobin C21H16ClFN4O5 361377-29-9 ChemService Inc. 99.5 
Pyraflufen-ethyl C15H13Cl2F3N2O4 129630-19-9 ChemService Inc. 99.2 
Trifloxystrobin C20H19F3N2O4 141517-21-7 ChemService Inc. 99.3 
Emamectin benzoate C49H77NO13 155569-91-8 ChemService Inc. 98.9 
 
N/A = Not commercially available 
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Table A.2: Optimized parameters for imaging spontaneous activity of 25-hpf fli1:egfp 
zebrafish using an ImageXpress® Micro (IXM) Widefield High-Content Screening 
System (Molecular Devices, Sunnyvale, CA). 
 
Tab Subset Tab 1 Subset Tab 2 Subset Tab 3 
Names and 
Description Spontaneous Activity   
Objective and 
Camera Magnification 2x Plan Apo  
 Camera Binning 2  
 Gain Gain 1 (1x)  Plate Matrical 0.17 mm glass   
 Number of rows 16  
 Well diameter (µm) 2900  
 Column offset (µm) 12000  
 Row offset (µm) 9200  
 Number of columns 24  
 Column spacing (µm) 4490  
 Row spacing (µm) 4490  
 Well depth (µm) 11500  
 Well shape Square  
 Plate length (mm) 127.8  
 Plate width (mm) 85.5  
 Plate height (mm) 12.5  Wells to visit 192 of 384   Sites to visit Site Acquisition Option Single site  Timelapse Number of timepoints 60  
 Perform time series for 
One well then 
the next  
 Interval 0.1 sec  
 Duration 6 sec  Acquisition Loop Number of wavelengths 1  
 Autofocus options (selected) 
Enable laser-
based focusing  
  
Enable image-
based focusing  
Autofocus Well to well autofocus 






 Algorithm Standard  
 Binning 2  
 
Allow image-based focusing 
for recovery from laser-   
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based well bottom failures 
 





Number of wells to attempt 
to initial find sample 1  
 Timelapse Autofocus 
First timepoint 
only  
W1 FITC Exposure Illumination setting FITC 




 Autofocus options 
Laser with z-
offset 185.14 µm 
Journals (2 selected) Before each image Custom Journal  
 After each image 
Custom 
Journal  
Display settings Manually set image display properties   
 
Display images during 
autofocus   
 
Display images during 




Table A.3: Optimized parameters for analyzing spontaneous activity of 25-hpf fli1:egfp 
zebrafish using EthoVision XT 9.0 (Noldus Information Technology, Leesburg, VA). 
 
Tab Subset Tab 1 Subset Tab 2 Subset Tab 3 Subset Tab 4 
Setup Experiment Settings Unit of distance cm  
  Unit of time s  





None   
 
Arena 
Settings Arena 1 
Select the entire 
well  
  Calibration Horizontal 0.29 cm 
   Vertical 0.29 cm 
  
Validate arena 
settings   
 
Trial Control 
Settings Rule begin  
Start-stop trial 
(green circle)  
  Action 
Start track (green 
triangle)  
  Action 
Stop track (red 
square)  
  Rule end 
Start-stop trial 
(red square)  
 
Detection 
Settings Method Grey Scaling  
  Detection range (5-11) to 255  
  
Video sample 
rate 10.0 per second  
  Subject contour Contour erosion 1 pixel 
   Contour dilation 1 pixel 
 Trial List Add trials 192  
  Add videos 
Choose 192 
videos from 
correct folder  
Acquisition Acquisition Acquisition setting 















acquisition)   
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Analysis Data Profiles 
Start box: 
Selection 











Profiles Mobility state   
  Outlier filter 
Averaging 
interval 4 





statistics for Highly mobile  
 Results 
Analysis 
Output Calculate  













Table A.4: Image success rates for analysis of spontaneous activity and total body area 
within control 25-hpf zebrafish embryos by column across three independent plates 
containing an initial sample size of 192 embryos per plate. 
 















1 16 100.0 16 100.0 16 100.0 
3 16 100.0 16 100.0 16 100.0 
5 16 100.0 16 100.0 16 100.0 
7 16 100.0 16 100.0 16 100.0 
9 16 100.0 16 100.0 16 100.0 
11 16 100.0 16 100.0 16 100.0 
13 16 100.0 16 100.0 16 100.0 
15 16 100.0 16 100.0 16 100.0 
17 16 100.0 16 100.0 16 100.0 
19 16 100.0 16 100.0 16 100.0 
21 16 100.0 16 100.0 16 100.0 
23 16 100.0 16 100.0 16 100.0 
2 
1 15 93.8 15 100.0 15 100.0 
3 16 100.0 16 100.0 16 100.0 
5 15 93.8 15 100.0 15 100.0 
7 16 100.0 16 100.0 16 100.0 
9 16 100.0 16 100.0 16 100.0 
11 16 100.0 16 100.0 16 100.0 
13 16 100.0 16 100.0 16 100.0 
15 16 100.0 16 100.0 16 100.0 
17 15 93.8 15 100.0 15 100.0 
19 14 87.5 14 100.0 14 100.0 
21 15 93.8 15 100.0 14 93.3 
23 15 93.8 15 100.0 15 100.0 
3 
1 16 100.0 16 100.0 16 100.0 
3 16 100.0 16 100.0 16 100.0 
5 16 100.0 15 93.8 15 93.8 
7 16 100.0 16 100.0 16 100.0 
9 16 100.0 16 100.0 16 100.0 
11 16 100.0 16 100.0 16 100.0 
13 16 100.0 16 100.0 16 100.0 
15 16 100.0 16 100.0 16 100.0 
17 16 100.0 16 100.0 16 100.0 
19 16 100.0 16 100.0 16 100.0 
21 16 100.0 16 100.0 16 100.0 
23 16 100.0 16 100.0 16 100.0 
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Table A.5: Summary of statistical results and overall effects on spontaneous activity for 












compared to both 
columns 1 and 23  





Nicotine 0.674 0.090 None No No 
Paraoxon 0.483 0.001 12.5 µM, 25 µM, and 50 µM No Yes 
Rotenone 0.699 0.752 None No No 






Thiram (low) 0.699 0.392 None No No 
Tefluthrin N/A N/A Not commercially available N/A N/A 
Butafenacil 0.164 0.113 None No No 
Pyridaben 1.000 0.106 None No No 
Flumetralin 0.472 0.097 None No No 
Fluthiacet-
methyl 0.422 0.716 None No No 
Abamectin 0.723 0.000 
3.125 µM, 6.25 
µM, 12.5 µM, 25 
µM, and 50 µM 
No Yes 
Fentin N/A N/A Insoluble in DMSO N/A N/A 
Propargite 0.050 0.027 ± None No No 
Milbemectin  N/A N/A Not commercially available N/A N/A 
Pyraclostrobin 0.588 0.804 None No No 
(Z,E)-
Fenpyroximate 0.821 0.492 None No No 
Tribufos 0.161 0.147 None No No 
Famoxadone 0.133 0.572 None No No 
Fluoxastrobin 0.857 0.492 None No No 
Pyraflufen-
ethyl 0.674 0.333 None No No 
Trifloxystrobin 0.782 0.171 None No No 
Emamectin 
benzoate 0.111 0.001 25 µM and 50 µM No Yes 
± 0.39, 25, and 50 µM treatments significantly reduced spontaneous activity compared to 





Figure A.1: Spontaneous activity (%) following exposure to 50 µL embryo media from 5 to 25 hpf in a 384-well plate containing 384 






Figure A.2: Flow diagram summarizing the exposure setup, image acquisition, and data extraction/analysis protocols for the HCS 
assay.  Using automated image acquisition protocols and parameters optimized for our ImageXpress® Micro Widefield High-Content 





Figure A.3: Comparison of the number of tail flips predicted by EthoVision and the 
number of tail flips counted manually within control 25-hpf zebrafish embryos across 






Figure A.4: Frequency of spontaneous activity (%) per column across three independent 
control plates with an initial size of 16 embryos per column and 12 columns per plate. 







Figure A.5: Nicotine does not affect spontaneous activity in the absence of effects on 
survival and total body area. Total body area data within each column are presented as 
mean ± SD. N = final number of embryos analyzed per column. Numbers above each bar 




Figure A.6: Rotenone does not affect spontaneous activity in the absence of effects on 
survival and total body area. Based on control survival and total body area criteria, 
hashed bars represent concentrations that were not analyzed for potential effects on 
spontaneous activity. Absence of a bar denotes 0% survival. Total body area data within 
each column are presented as mean ± SD. N = final number of embryos analyzed per 
column. Asterisk denotes significant difference in total body area from both vehicle 
controls (p<0.05). Numbers above each bar denote percent spontaneous activity within 




Figure A.7: Thiram (high) does not affect spontaneous activity in the absence of effects 
on survival and total body area. Based on control survival and total body area criteria, 
hashed bars represent concentrations that were not analyzed for potential effects on 
spontaneous activity. Absence of a bar denotes 0% survival. Total body area data within 
each column are presented as mean ± SD. N = final number of embryos analyzed per 
column. Asterisk denotes significant difference in total body area from both vehicle 
controls (p<0.05). Numbers above each bar denote percent spontaneous activity within 




Figure A.8: Thiram (low) does not affect spontaneous activity in the absence of effects 
on survival and total body area. Based on control survival and total body area criteria, 
hashed bars represent concentrations that were not analyzed for potential effects on 
spontaneous activity. Total body area data within each column are presented as mean ± 
SD. N = final number of embryos analyzed per column. Numbers above each bar denote 




Figure A.9: Butafenacil does not affect spontaneous activity in the absence of effects on 
survival and total body area. Total body area data within each column are presented as 
mean ± SD. N = final number of embryos analyzed per column. Numbers above each bar 





Figure A.10: Pyridaben does not affect spontaneous activity in the absence of effects on 
survival and total body area. Based on control survival and total body area criteria, 
hashed bars represent concentrations that were not analyzed for potential effects on 
spontaneous activity. Absence of a bar denotes 0% survival. Total body area data within 
each column are presented as mean ± SD. N = final number of embryos analyzed per 
column. Asterisk denotes significant difference in total body area from both vehicle 
controls (p<0.05). Numbers above each bar denote percent spontaneous activity within 




Figure A.11: Flumetralin does not affect spontaneous activity in the absence of effects 
on survival and total body area. Total body area data within each column are presented as 
mean ± SD. N = final number of embryos analyzed per column. Numbers above each bar 




Figure A.12: Fluthiacet-methyl does not affect spontaneous activity in the absence of 
effects on survival and total body area. Based on control survival and total body area 
criteria, hashed bars represent concentrations that were not analyzed for potential effects 
on spontaneous activity. Absence of a bar denotes 0% survival. Total body area data 
within each column are presented as mean ± SD. N = final number of embryos analyzed 
per column. Asterisk denotes significant difference in total body area from both vehicle 
controls (p<0.05). Numbers above each bar denote percent spontaneous activity within 




Figure A.13: Propargite does not affect spontaneous activity in the absence of effects on 
survival and total body area. Total body area data within each column are presented as 
mean ± SD. N = final number of embryos analyzed per column. Numbers above each bar 




Figure A.14: Pyraclostrobin does not affect spontaneous activity in the absence of effects 
on survival and total body area. Based on control survival and total body area criteria, 
hashed bars represent concentrations that were not analyzed for potential effects on 
spontaneous activity. Absence of a bar denotes 0% survival. Total body area data within 
each column are presented as mean ± SD. N = final number of embryos analyzed per 
column. Asterisk denotes significant difference in total body area from both vehicle 
controls (p<0.05). Numbers above each bar denote percent spontaneous activity within 




Figure A.15: (Z,E)-Fenpyroximate does not affect spontaneous activity in the absence of 
effects on survival and total body area. Based on control survival and total body area 
criteria, hashed bars represent concentrations that were not analyzed for potential effects 
on spontaneous activity. Absence of a bar denotes 0% survival. Total body area data 
within each column are presented as mean ± SD. N = final number of embryos analyzed 
per column. Asterisk denotes significant difference in total body area from both vehicle 
controls (p<0.05). Numbers above each bar denote percent spontaneous activity within 




Figure A.16: Tribufos does not affect spontaneous activity in the absence of effects on 
survival and total body area. Total body area data within each column are presented as 
mean ± SD. N = final number of embryos analyzed per column. Numbers above each bar 




Figure A.17: Famoxadone does not affect spontaneous activity in the absence of effects 
on survival and total body area. Based on control survival and total body area criteria, 
hashed bars represent concentrations that were not analyzed for potential effects on 
spontaneous activity. Absence of a bar denotes 0% survival. Total body area data within 
each column are presented as mean ± SD. N = final number of embryos analyzed per 
column. Asterisk denotes significant difference in total body area from both vehicle 
controls (p<0.05). Numbers above each bar denote percent spontaneous activity within 




Figure A.18: Fluoxastrobin does not affect spontaneous activity in the absence of effects 
on survival and total body area. Based on control survival and total body area criteria, 
hashed bars represent concentrations that were not analyzed for potential effects on 
spontaneous activity. Absence of a bar denotes 0% survival. Total body area data within 
each column are presented as mean ± SD. N = final number of embryos analyzed per 
column. Numbers above each bar denote percent spontaneous activity within that 




Figure A.19: Pyraflufen-ethyl does not affect spontaneous activity in the absence of 
effects on survival and total body area. Total body area data within each column are 
presented as mean ± SD. N = final number of embryos analyzed per column. Numbers 




Figure A.20: Trifloxystrobin does not affect spontaneous activity in the absence of 
effects on survival and total body area. Based on control survival and total body area 
criteria, hashed bars represent concentrations that were not analyzed for potential effects 
on spontaneous activity. Absence of a bar denotes 0% survival. Total body area data 
within each column are presented as mean ± SD. N = final number of embryos analyzed 
per column. Asterisk denotes significant difference in total body area from both vehicle 
controls (p<0.05). Numbers above each bar denote percent spontaneous activity within 




 MECHANISTIC STUDIES WITH ABAMECTIN 
B.1 MATERIALS AND METHODS 
B.1.1 CHEMICALS 
Bicuculline, picrotoxin and strychnine were purchased from ChemService, Inc. 
(West Chester, PA). All stock and working solutions were prepared as described in 
Chapter 3, Section 3.2.2. 
 
B.1.2 PRETREATMENT OF ZEBRAFISH EMBRYOS WITH LIGAND-GATED CHLORIDE CHANNEL 
ANTAGONISTS 
We used bicuculline and picrotoxin - two commercially available GABA receptor 
antagonists - and strychnine – a rodenticide that antagonizes the glycine receptor - to test 
whether abamectin-induced hypoactivity was mediated through GABA or glycine 
receptors. To identify the maximum tolerated concentration that did not adversely impact 
spontaneous activity, range-finding exposures for bicuculline (3.125-25 µM), picrotoxin 
(0.625-5 µM), and strychnine (0.39-3.125) alone were first conducted under static 
exposure conditions in 50 mL beakers as described in Chapter 3, Section 3.2.3. Based on 
these range-finding exposures, the final no-effect concentration used for these 
experiments was 12.5 µM, 1.25 µM, and 3.125 µM for bicuculline, picrotoxin, and 
strychnine, respectively. Then, pretreatment exposures were conducted as described in 
Chapter 3, Section 3.2.5. 
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B.1.3 IN SITU ASSESSMENT OF GABA WITHIN 25-HPF ZEBRAFISH EMBRYOS 
Wildtype (5D) embryos were exposed in triplicate glass beakers to either vehicle 
(0.1% DMSO) or 0.5 µM abamectin from 5-25 hpf at 28°C. Live embryos were then 
dechorionated by incubating embryos in 0.5 mg/mL pronase for 20 min on a shaker at 
100 rpm. Embryos were then washed in RO water and fixed overnight in 4% 
paraformaldehyde. Fixed embryos were permeabilized by incubating in cold acetone at -
20°C for 15 minutes, and then rinsed four times in phosphate-buffered saline (PBS)/0.1% 
Tween-20 (PBST) for 5 min per wash. Permeabilized embryos were incubated in fresh 
blocking buffer (PBST/2% sheep serum/2 mg/ml bovine serum albumin) for 4 hours at 
room temperature with gentle agitation, and then incubated overnight at 4°C with gentle 
agitation in blocking buffer containing a 1:20 dilution of znp-1 IgG2a (Invitrogen) and a 
1:500 dilution of anti-GABA (Sigma Aldrich). znp-1 IgG2a is a zebrafish-specific 
antibody that recognizes cell bodies and axons of primary motoneurons in 25-hpf 
zebrafish (Pike et al., 1992; Trevarrow et al., 1990). Following primary antibody 
incubation, embryos were washed five times with gentle agitation in PBST at room 
temperature for 15 minutes each. Embryos were incubated overnight at 4°C with gentle 
agitation in blocking buffer containing a 1:500 dilution of Alexa Fluor 488 (AF488)-
conjugated goat anti-mouse (Invitrogen) to visualize znp-1 localization in situ and a 
1:2000 dilution of Alexa Fluor 555 (AF555-conjugated goat anti-rabbit (H+L) 
(Invitrogen) to visualize anti-GABA localization in situ. Finally, secondary antibody-
labeled embryos were washed five times with gentle agitation in PBST at room 
temperature for 15 minutes each, and then stored in PBS at 4°C until imaging. Labeled 
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embryos were imaged at 10X magnification using a FITC or TRITC filter cube and 
Olympus BX51 Research System Microscope equipped with an Olympus DP72 Digital 
Color Camera and Olympus DP2-BSW Imaging Software. 
 
B.1.4 WHOLE MOUNT IN SITU HYBRIDIZATION 
To localize gabra1 transcripts within developing zebrafish embryos, whole-mount 
in situ hybridization was performed as previously described (Thisse and Thisse, 2008). 
The following PCR primers were used to amplify a 1020-bp gabra1 fragment: forward 
primer 5’-TGCGATACATTCCGGGTGAG-3’, reverse primer 5’-GGGAGAGAGT 
TTCTTGCGCT-3’. Per manufacturer’s instructions, a 1020-bp gabra1 fragment was 
PCR-amplified from approximately 100 ng of cDNA using GoTaq Hot Start Green 
Master Mix (Promega) and the following PCR reaction conditions: 2 minutes at 95°C 
followed by 35 cycles of 95°C for 30 seconds, 52°C for 30 seconds, and 72°C for 90 
seconds, with a final extension step at 72°C for 5 minutes. Amplified 1020-bp gabra1 
fragments were then gel purified and ligated into pGEM-T Easy Vector System 
(Promega). JM109 Competent Cells (Promega) were transformed with the resulting 
vector and plasmids were purified from transformed colonies using a PureYield Plasmid 
Miniprep System (Promega). Per manufacturer’s instructions, RNA probes were 
developed using a Digoxigenin (DIG) RNA Labeling Kit (Roche Applied Science, 
Indianapolis, IN). For antisense hybridizations, purified plasmid was linearized with NcoI 
(New England Biolabs, Ipswich, MA), and SP6 polymerase was used to develop DIG-
labeled antisense gabra1 RNA probes. To assess the specificity of gabra1-specific 
antisense probes, purified plasmid was linearized with SalI (New England Biolabs), and 
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T7 polymerase was used to develop DIG-labeled sense (negative control) gabra1 RNA 
probes. Antisense and sense RNA probes were purified using illustraProbeQuant G-50 
Micro Columns (GE Healthcare, Piscataway, NJ).  
Embryos representing three developmental stages (5, 10, and 23 hpf) were 
dechorionated by incubating embryos in 0.5 mg/mL pronase for 20 min on a shaker at 
100 rpm. Embryos were then rinsed in RO water and fixed in 4% paraformaldehyde/PBS 
overnight at 4°C. Fixed embryos were then dehydrated in 100% methanol (MeOH) for 15 
min at room temperature and stored at -20°C until in situ hybridization procedures. 
Dehydrated embryos were rehydrated with 75, 50, and 25% MeOH/PBS and then rinsed 
with PBS containing 0.1% Tween-20 (PBST). Embryos were permeabilized with 
proteinase K (10 µg/mL), refixed with 4% paraformaldehyde/PBS for 20 minutes, and 
then washed four times with PBST. Embryos were prehybridized with 700 µL of 
hybridization mixture (HM) (50% deionized formamide; 5x saline sodium citrate (SSC); 
0.1% Tween-20; 50 µg/mL heparin; 150 µg/mL RNase-free  transfer RNA (tRNA); pH 
6.0) for 3.5 hours in a 45°C water bath. Prehybridized embryos were then hybridized 
overnight at 45°C in 200 µL of HM containing 50 ng of DIG-labeled sense or antisense 
gabra1 RNA probe. Following hybridization, embryos were thoroughly washed with HM 
(without heparin and RNase-free tRNA), SSC, and PBST. Embryos were incubated for 
3.5 hours at room temperature in blocking buffer (PBST; 2% sheep serum; 2 mg/mL 
bovine serum albumin). Embryos were then either: 
1) Incubated overnight at 4°C in alkaline phosphatase-conjugated sheep anti-DIG 
Fab fragments diluted 1:4000 with blocking buffer. Antibody-labeled embryos 
were then washed with PBST and alkaline Tris buffer, and DIG localization 
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visualized with a nitroblue tetrazolium chloride and 5-bromo-4-chloro-3-indolyl 
phosphate (NBT/BCIP) substrate solution (Roche Applied Science). Following 
color development, embryos were incubated within stop solution (13 PBS; 1mM 
EDTA; 0.1% Tween-20; pH 5.5) to terminate enzymatic reactions. 
2) Incubated overnight in the dark at 4°C in Anti-DIG Flourescein diluted 1:200 
with blocking buffer. Antibody-labeled embryos were then washed with PBST.  
All embryos were imaged using an Olympus BX51 Research System Microscope 
equipped with an Olympus DP72 Digital Color Camera and Olympus DP2-BSW Imaging 
Software. 
 
B.1.5 FLUORESCENT IMAGING PLATE READER (FLIPR) MEMBRANE POTENTIAL ASSAY 
To evaluate changes in membrane potential, we used the FLIPR Membrane 
Potential Assay Kit (Molecular Devices). Fli1:egfp embryos (20 per beaker) were first 
incubated in 1x EM until 22 hpf, then incubated  in a 1:1 ratio of 1x EM to Red Assay 
Reagent for 1 hour at room temperature in the dark. Live embryos were then washed 
twice with 1x EM and exposed to either vehicle (0.1% DMSO) or 0.5 µM abamectin 
from 23-25 hpf in the dark at room temperature. At 25 hpf, embryos were imaged using a 
TRITC filter cube to assess fluorescence within the embryos and an Olympus MVX10 
MacroView stereomicroscope equipped with an Olympus DP72 Digital Color Camera 






B.2.1 PRETREATMENT OF ZEBRAFISH EMBRYOS WITH LIGAND-GATED CHLORIDE CHANNEL 
ANTAGONISTS 
Based on initial range-finding exposures with bicuculline, picrotoxin, and 
strychnine, we selected 12.5 µM, 250 µM, and 3.125 µM of bicuculline, picrotoxin and 
strychnine, respectively, as the maximum tolerated concentration based on the absence of 
effects on spontaneous activity. In pretreatment experiments with bicuculline, picrotoxin, 
and strychnine, average survival within all exposure groups was ≥95%. Spontaneous 
activity within vehicle controls was at least 79% and hypoactivity was observed within 
abamectin-exposed embryos pretreated with vehicle, bicuculline (Figure B.1), picrotoxin 
(Figure B.2), or strychnine (Figure B.3). Therefore, abamectin-induced hypoactivity was 
not blocked by pretreatment with non-toxic concentrations of these commercial GABA 
receptor antagonists or glycine receptor antagonist. Due to the high water solubility of the 
GABA receptor antagonists, it is thought that this lack of effect may be due to limited to 
no embryonic uptake. However, strychnine is a fairly hydrophobic compound and was 
likely taken up by the embryos, suggesting that abamectin-induced hypoactivity is not 
mediated through the glycine receptor. 
 
B.2.2 IN SITU ASSESSMENT OF GABA WITHIN 25-HPF ZEBRAFISH EMBRYOS 
To assess the presence of GABA in situ within 25-hpf zebrafish embryos, we used 
whole-mount immunohistochemistry. GABAergic neurons were detected within the 
spinal cord of both vehicle and abamectin-exposed embryos, but not in the primary 
motoneurons. However, no detectable differences were observed when comparing the 
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two treatments (Figure B.4) and there was a lot of individual embryo variation. Due to 
the background GABA staining in the trunk musculature it was difficult to assess the 
specificity of GABA localization in situ. 
 
B.2.3 WHOLE-MOUNT IN SITU HYBRIDIZATION  
To assess the spatiotemporal distribution of gabra1 expression, we conducted 
whole-mount in situ hybridization at 25 hpf using sense and antisense probes against 
gabra1 mRNA. However, attempts to use colorimetric and fluorescent detection were 
unsuccessful and we were unable to determine gabra1 localization. 
 
B.2.4 FLIPR MEMBRANE POTENTIAL ASSAY 
 To assess voltage changes within zebrafish embryos after exposure to vehicle or 
abamectin, we used a fluorescence-based assay that detects changes in ion channel 
modulation through increases or decreases in the fluorescent signal as cellular membrane 
potential changes. During membrane depolarization, indicator dye follows the positively 
charged ions resulting in increased cellular fluorescence. During hyperpolarization, 
fluorescence intensity decreases due to the indicator dye following positive ions out of 
the cell. After incubation with Red Assay Reagent and subsequent exposure to vehicle or 
abamectin, no detectable differences in fluorescence were observed when comparing the 
two treatments (Figure B.5). Although we expected to see lower fluorescence in 
abamectin-exposed embryos due to hyperpolarization, this assay was designed for 






Figure B.1: Abamectin-induced hypoactivity is not blocked by pretreatment of embryos 
with non-toxic concentrations of bicuculline. (A) Survival and (B) spontaneous activity at 
25 hpf following exposure to vehicle (0.1% DMSO) or 0.5 µM abamectin (23-25 hpf) 
with or without bicuculline pre-treatment (5-23 hpf). Plus (+) or minus (-) signs indicate 
the presence or absence, respectively, of a chemical for each treatment. Numbers above 
each bar denote percent spontaneous activity. Asterisk (*) denotes significant difference 






Figure B.2: Abamectin-induced hypoactivity is not blocked by pretreatment of embryos 
with non-toxic concentrations of picrotoxin. (A) Survival and (B) spontaneous activity at 
25 hpf following exposure to vehicle (0.1% DMSO) or 0.5 µM abamectin (23-25 hpf) 
with or without picrotoxin pre-treatment (5-23 hpf). Plus (+) or minus (-) signs indicate 
the presence or absence, respectively, of a chemical for each treatment. Numbers above 
each bar denote percent spontaneous activity. Asterisk (*) denotes significant difference 







Figure B.3: Abamectin-induced hypoactivity is not blocked by pretreatment of embryos 
with non-toxic concentrations of strychnine. (A) Survival and (B) spontaneous activity at 
25 hpf following exposure to vehicle (0.1% DMSO) or 0.5 µM abamectin (23-25 hpf) 
with or without strychnine pre-treatment (5-23 hpf). Plus (+) or minus (-) signs indicate 
the presence or absence, respectively, of a chemical for each treatment. Numbers above 
each bar denote percent spontaneous activity. Asterisk (*) denotes significant difference 






Figure B.4: Fixed wildtype (5D) embryos exposed to vehicle (0.1% DMSO) or 
abamectin (0.5 µM) from 5-25 hpf and incubated in znp-1 and anti-GABA antibody 
overnight at 4°C followed by an overnight incubation in goat anti-mouse IgG2a Alexa 





Figure B.5: Fli1:egfp embryos incubated in Red Assay Reagent and then exposed to 
vehicle (0.1% DMSO) or abamectin (0.5 µM) from 23-25 hpf. Images were taken using a 
TRITC filter cube and no difference in fluorescence was observed when comparing the 
two treatments. 
 
